Transcriptional regulation of ARF tumor suppressor by Zeng, Yaxue
  
Transcriptional Regulation of ARF Tumor Suppressor  
 
 
by 
Yaxue Zeng 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Biochemistry and Biophysics 
 
 
 
 
Chapel Hill 
2010 
 
 
 
Approved by 
 
Advisor: Dr. Yue Xiong 
 
 
Reader: Dr. Jeanette Cook  
 
 
Reader: Dr. Robert Duronio 
 
 
Reader: Dr. William Marzluff 
 
 
Reader: Dr. Norman Sharpless
ii 
ABSTRACT 
Yaxue Zeng: Transcriptional Regulation of ARF tumor suppressor 
(under the direction of Dr. Yue Xiong) 
 
The expression of tumor suppressor ARF is tightly repressed during normal cell growth in 
human and mouse at young age and is activated by oncogenic insults and during aging, 
resulting in p53 activation and cell cycle arrest to prevent hyperproliferation. The 
mechanisms of both transcriptional repression and activation of ARF are not well 
understood. In my dissertation study, I showed that in mouse, p53 binds to Arf promoter 
and represses Arf expression and this repression requires the function of both histone 
deacetylase (HDAC) and polycomb group (PcG) proteins. Conversely, I demonstrated 
that p53 is required for both HADC and PcG to repress Arf expression. Bindings of both 
HDAC and PcG to Arf are disrupted by inactivation of p53 and can be restored in p53 
null MEFs by the reintroduction of wild-type, but not mutant p53. In the latter part of my 
study, I found that the regulation of ARF expression is quite different in human. While 
p53 still represses human ARF, HDAC and PcG are not repressors of ARF, instead, ARF 
expression can be activated by treatment of DNA demethylation drugs. In addition, my 
study on the activation of ARF expression in response to oncogenic stress demonstrated a 
dynamic binding of E2F1 and E2F3 on the ARF locus accompanying the increased ARF 
transcription.  
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INTRODUCTION
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The ARF/p16 locus is important in tumor suppression 
The ARF/p16 locus on chromosome 9p21, which is genetically altered in an 
estimated 30 – 40% of human cancers,  is involved in a wide range of tumors, including 
melanoma, pancreatic adenocarcinoma, bladder carcinoma, glioblastoma, non-small cell 
lung cancer and oropharyngeal cancer(Gil and Peters, 2006; Kim and Sharpless, 2006; 
Sharpless, 2005). This locus consists of two overlapping genes that encode two unrelated 
tumor suppressor proteins, Arf (also known as p19 for mice and p14 for human) and p16 
(also called INK4a). p16 and Arf have different first exons but share the second and third 
exons. As the two proteins are encoded in different reading frames, p16 and Arf have no 
amino acid homology (Quelle et al., 1995) (Figure 1.1).  
 
 
 
Figure 1.1. The Ink4a/Arf locus. Alternative first exons (1α and 1β) are 
transcribed from different promoters (arrows), but spliced to the same 
acceptor site in exon 2, which is translated in alternative frames. Ink4a 
coding sequences in exons 1α, 2 and 3 are denoted by light shading, and 
Arf coding sequences in exons 1β and 2 are indicated by dark blue 
shading. The schematic is not drawn to scale, and in both the human and 
mouse genomes, exons 1α and 1β are separated by >15 kb. (Sherr, 2001). 
 
The two proteins encoded by INK4A/ARF locus play independent roles in tumor 
suppression. p16 is an inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Bound 
by p16, CDK4 and CDK6 can not associate with D-cyclin to mediate phosphorylation of 
3 
Rb family members. When hypophosphorylated, Rb proteins bind to and inhibit E2F1 for 
G1 cell cycle arrest (Quelle et al., 1995). On the other hand, Arf associates with Mdm2 
and stabilizes p53 by inhibiting the E3 ubiquitin ligase activity of Mdm2, therefore the 
proteasome-dependent degradation of p53 by Mdm2 is blocked (Pomerantz et al., 1998; 
Zhang et al., 1998)  (Figure 1.2)  
The INK4a/ARF locus plays an essential role in cell senescence, although the 
detailed mechanism is unknown. The two genes are expressed at very low levels during 
embryogenesis or in young tissues, but they become epigenetically de-repressed with cell 
aging (Krishnamurthy et al., 2004). Also, under oncogenic stresses, the expression of p16 
and Arf is activated to induce premature senescence or apoptosis, which acts as a defense 
mechanism against the transformation effect of oncogenic signals (Sherr, 2001). (Figure 
1.2)  
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Figure 1.2. Increased levels of p16Ink4a or p19Arf result in cell-cycle arrest 
by p16-Rb pathway and Arf-p53 pathway individually.(Lloyd, 2000)   
 
The ARF-Mdm2-p53 pathway is tightly regulated by feedback loops 
The transcription factor p53 mediates cellular response to a wide range of 
genotoxic and growth stresses, including DNA damage and oncogenic insults (Laptenko 
and Prives, 2006). Activated p53 increases the expression of numerous genes and elicits 
three distinct types of cellular outcomes—temporary cell cycle arrest, permanent cell 
senescence and apoptotic cell death—to prevent damaged or stressed cells from 
continuing proliferation (Riley et al., 2008). It is generally believed that escape from the 
p53-mediated checkpoint pathway is a necessary step for the development of most, if not 
all, types of tumors (Hollstein et al., 1991; Levine et al., 1991). 
Much has been learned on the function of p53 in both senescence and apoptosis 
(Vousden and Prives, 2009). Equally important is the regulation of p53 in causing 
temporary cell cycle arrest. Unlike senescence or apoptosis, both of which are irreversible, 
a mechanism to inhibit activated p53 is critically important in releasing temporarily 
arrested cells to resume the cell cycle once the damage is repaired or stress is relieved. 
One such mechanism to reversibly regulate p53 is the feedback inhibition loop in which 
p53 activates the expression of its principle inhibitor (Barak et al., 1993a; Otto and 
Deppert, 1993; Wu et al., 1993a), MDM2, which binds to and inhibits the function of p53 
through both repressing the transactivating activity of p53 (Momand et al., 1992; Thut et 
al., 1997), as well as targeting p53 for ubiquitin-mediated degradation (Haupt et al., 1997; 
Honda et al., 1997; Kubbutat et al., 1997). 
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The potent activity of ARF in binding to and inhibiting the function of MDM2 
raises the question on how p53 is reversibly regulated in oncogenically insulted cells. In 
these cells, ARF, if continuously expressed, would prevent MDM2 from inhibiting p53 
and thus disrupt the MDM2-p53 feedback regulatory loop. It was noted early on that in 
both human (Robertson and Jones, 1998; Stott et al., 1998) and mouse cells (de Stanchina 
et al., 1998; Zindy et al., 1998), ARF gene expression exhibits a strong inverse correlation 
with the functional status of p53, suggesting a possible feedback repression of ARF 
expression by p53 (Figure 1.3). 
 
 
 
 
 
 
 
 
Figure 1.3. Two negative feedback loops in the ARF-Mdm2-p53 pathways. 
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Acetylation and methylation are two major histone modifications to regulate gene 
expression 
The nucleosome is the fundamental unit of chromatin and it comprises an octamer 
of four core histones (H3, H4, H2A, H2B) wrapped by 146 base pair of DNA. The N-
terminal tails of histone are subject to posttranslational modifications including 
acetylation, methylation, phosphorylation, and ubiquitination. Covalently modified 
histones can either recruit regulatory proteins or control the accessibility of transcription 
machinery.  
Acetylation/deacetylation changes the charges of histone therefore affects gene 
expression through influencing chromatin conformation. Acetylation of histone by 
histone acetyl transferase (HAT) is always associated with activation of transcription, 
while deacetylation of histone by histone deacetylase (HDAC) is usually correlates with 
transcriptional repression (Kouzarides, 2007). There are four classes of histone 
deacetylases in mammals and more than 10 HDACs have been identified. Their 
deacetylation activity can be specifically inhibited by trichostatin A (TSA, inhibiting 
HDAC Class I/II), sodium butyrate (NaB, inhibiting HDAC Class I/II) or nicotinamide 
(NAM, inhibiting HDAC Class III) (Gallinari et al., 2007). HDACs has been found in 
many transcription repression complexes and the interactions of Class I HDAC (HDAC1, 
HDAC2 HDAC3) with p53, Rb and PcG proteins in transcriptional repression have been 
reported individually (Luo et al., 1998; Murphy et al., 1999; Tie et al., 2001; van der Vlag 
and Otte, 1999). 
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Lysine methylation of histone has been implicated in both gene activation and 
repression. In mammals, methylation at histone H3K4, H3K36 and H3K79 have been 
correlated with gene activation, while methylation at H3K9, H3K27 and H4K20 are 
repressive marks. For a long time, people had considered histone methylation an 
irreversible process, until the finding of  histone demethylases LSD1 , RBP2, 
SMCX/JARID1C  and Jmj-domain-containing proteins, etc (Iwase et al., 2007; Klose et 
al., 2007; Pasini et al., 2008; Shi et al., 2004; Tahiliani et al., 2007; Yamane et al., 2007) . 
Recent research has linked two histone modifying complexes, histone 
deacetylases (HDAC) (Gonzalez et al., 2006; Matheu et al., 2005; Yarosh et al., 2008),  
and polycomb proteins (PcG) (Bracken et al., 2007a; Bruggeman et al., 2005; Jacobs et 
al., 1999a; Kotake et al., 2007b; Molofsky et al., 2005; Park et al., 2003), to the 
repression of Arf expression. How these two histone modifying complexes, which do not 
recognize a specific DNA sequence, are recruited to the Arf locus is not known. 
 
The ARF/p16 locus is repressed by Polycomb Group (PcG) Proteins  
PcG proteins are characterized as epigenetic silencers in embryogenesis, cell 
cycle regulation, X-inactivation and hematopoiesis (Caretti et al., 2004; Heard, 2004; 
Lessard et al., 1999; Leung et al., 2004; van der Lugt et al., 1994). Control of cell 
proliferation by polycomb group (PcG) proteins is essential for cellular homeostasis, 
while the expression of PcG proteins is often deregulated in human cancer (Valk-
Lingbeek et al., 2004). The polycomb group proteins are a set of proteins with diverse 
structures but similar functions, linking histone modifications to transcriptional 
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repression (Lund and van Lohuizen, 2004; Otte and Kwaks, 2003). They participate in 
two distinct protein complexes, polycomb repressive complexes 1 and 2 (PRC1 and 
PRC2). In humans, PRC2 contains EZH2, EED, SUZ12 and RbAp48, while PRC1 
contains at least six different subunits: the polyhomeotic- (HPH 1-3), the polycomb-
/CBX (HPC1/CBX2, HPC2/CBX4, HPC3/CBX8, CBX6 and CBX7), the RING1-and 2-
(Ring 1A/B), the posterior sex comb-(Bmi1, Mel18, MBLR and NSPC1) and sex comb 
on midleg (Scml1-2)(Cao et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002; 
Levine et al., 2002; Muller et al., 2002).  
The SET domain-containing EZH2 of PRC2 has histone methyltrasferase activity 
and di-and tri-methylates lysine 27 on histone 3. This epigenetic mark is specifically 
recognized by the chromodomain of polycomb (Pc), a PRC1 component. Therefore the 
maintenance complex PRC1 is recruited to the targeted chromatin through binding of the 
chromodomain of Pc to tri-methylated H3K27 (Cao et al., 2002). PRC1 is an E3 ubiquitin 
ligase complex and it monoubiquitinates nucleosomal histone H2A at lysine 119. Ring1B 
is the catalytic subunit while Ring1A and Bmi1 can stimulate the ubiquitination process 
(Cao et al., 2005b; Wang et al., 2004a; Wang et al., 2004c). Both the trimethylated 
H3K27 and mono-ubiquitinated H2A-K119 are repressive epigenetic markers that inhibit 
transcription initiation. Therefore the PRC2 and PRC1 cooperate to maintain stable 
transcriptional repression. (Figure 1.4)  
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Figure 1.4.  Composition and function of PRC1 and PRC2 complexes. 
The epigenetic mark H3K27 trimethylation established by PRC2 are 
recognized by the PRC1. Ac, acetylation; Me, methylation (Gil and 
Peters, 2006). 
 
Bmi1, first identified by its ability to cooperate with myc in the induction of 
mouse lymphomas (Haupt et al., 1991; van Lohuizen et al., 1991), is required for self-
renewal and post-natal maintenance of hematopoietic stem cell and neural stem cell 
(Molofsky et al., 2005; Park et al., 2003). In mice, the absence of Bmi1 expression results 
in neurological defects, proliferative defects in progression into S phase of cell cycle and 
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premature senescence. On the other hand, overexpression of Bmi1 can delay the onset of 
senescence in both human and mice fibroblasts by repressing the Ink4a/Arf locus. And 
cooperating with H-rasG12V, its overexpression can lead to neoplastic transformation 
(Jacobs et al., 1999a). Recently, it has been shown that, in mouse primary cells Bmi1 and 
Ring2 can bind directly to both the p16 promoter and Arf promoter to repress the 
transcription of the Ink4a/Arf locus and they are dissociated from this locus in senescent 
cells (Bracken et al., 2007a; Kotake et al., 2007b). Other PcG members, such as Ezh2, 
Suz12, CBX7, CBX8 and Mel-18 are also found to bind and repress the Ink4a/Arf locus 
(Dietrich et al., 2007; Elderkin et al., 2007; Gil et al., 2004; Maertens et al., 2009). 
Not only was the binding of PcG members detected on Ink4a locus, it was also 
found that Rb is an essential component in the PcG-mediated p16 repression. Inactivation 
of Rb family proteins disrupts H3K27 trimethylation and Bmi1/Ring1B binding to the 
p16 locus, accompanied by released p16 expression (Kotake et al., 2007b). This 
constitutes a negative feedback loop in the p16-Rb pathway (Figure 1.5), also provides 
inspiring hints for the regulation of ARF-p53 pathway.  
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Figure 1.5.  The Rb family is required for PcG to repress p16 locus. 
 
The ARF/p16 locus is activated by oncogenic/proliferative stress 
The ARF/p16 locus can be activated by various oncogenic insults or proliferative 
stress, leading to either apoptosis or premature senescence. Therefore ARF/p16 are 
effective barriers to tumor formation by mediating an oncogenic checkpoint pathway to 
prevent oncogenic-stimulated cells from hyperproliferation (Kim and Sharpless, 2006; 
Sherr, 1998). 
Ras was the first oncogenic signal being linked with transcriptional activation of 
INK4a (Serrano et al., 1997). Oncogenic Ras activates INK4a in both mouse and human 
fibroblasts, leading to premature senescence. Of the several signaling pathways activated 
by Ras, it is the RAF-MEK-ERK kinase cascade that is responsible for activating INK4a 
and inducing senescence (Lin et al., 1998; Michaloglou et al., 2005; Ohtani et al., 2001; 
Zhu et al., 1998), through either phosphorylation and enhanced binding of Ets2 
transcription factor to the INK4a locus, or a secondary signal by the p38 family of stress-
activated kinase (Deng et al., 2004; Haq et al., 2002; Iwasa et al., 2003; Wang et al., 
2002). Ras can also activate Arf expression in MEFs (Groth et al., 2000; Lin and Lowe, 
2001; Palmero et al., 1998), likely by increasing binding of the transcriptional factor 
DMP1 to Arf locus (Inoue et al., 1999; Sreeramaneni et al., 2005).  However, oncogenic 
Ras can not induce ARF expression in human cells (Berkovich et al., 2003; Brookes et al., 
2002; Ferbeyre et al., 2000; Wei et al., 2001).  
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The proliferative effects of Myc are usually countered by apoptosis (Evan et al., 
1992). Although Myc has the potential to regulate the ARF/p16 locus by direct 
association since it is a DNA-binding transcriptional factor, its effects on ARF/p16 
regulation are complicated by the fact that it can also activate Bmi1, the repressor of 
ARF/p16 locus (Guney et al., 2006). Myc is able to up-regulate INK4a expression in 
human cells, but not in MEFs despite the fact that mouse Arf expression can be induced 
by Myc (Drayton et al., 2003; Grandori et al., 2003; Zindy et al., 1998).   
The hyperpoliferative stress produced by E2F is also able to potently induce ARF 
expression, and several E2Fs has been detected at ARF promoter by ChIP analysis 
(Aslanian et al., 2004; Kel et al., 2001; Komori et al., 2005; Lomazzi et al., 2002). The 
detailed aspects of E2F-mediated regulation of ARF expression will be discussed in the 
following section.  
Some recent reports have also linked histone modifiers to the oncogenic 
activation of INK4a/Arf. Overexpression of oncogenic Ras can dissociate Bmi1 from the 
INK4a locus, which is accompanied by decreased trimethylation of H3K27 and increased 
trimethylation of H3K4, whereas the binding of H3K4 methyltransferase MLL1 to INK4a 
is not changed (Kotake et al., 2009). The expression of the H3K27 demethylase JMJD3 is 
induced upon Ras-mediated oncogenic stress and JMJD3 is recruited to the INK4a locus 
and contributes to the transcriptional activation of INK4a in human cells (Agger et al., 
2009).  
 
ARF locus is regulated by E2F family 
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In normal cells, the E2F family, together with Rb family members, coordinates 
the expression of genes essential for cell cycle progression (which are usually called 
classical E2F target). During quiescence, the expression of classical E2F targets is 
prevented by either of the two mechanisms: 1) the transcriptional activity of the 
activating E2Fs – E2F1, E2F2 and E2F3a – is inhibited by Rb; 2) the repressing E2Fs – 
E2F4 and E2F5 – recruits p130 or p107 together with corepressor complexes to gene 
target. When mitogen signal stimulates quiescent cells to process from G1 to S phase, the 
activity of E2F1/2/3a is released from Rb-mediated repression due to the 
hyperphosphorylation of Rb by cyclin D/CDK4,6 and cyclin E/CDK2, therefore the 
genes necessary for G1/S progression are actively expressed (Dyson, 1998; Nevins, 1998; 
Trimarchi and Lees, 2002).  
 
 
 
 
 
Figure 1.6.  The G1 cell cycle control by Rb-E2F.  
 
The E2F3 gene encodes two distinct isoforms, E2F3a and E2F3b, by using 
different promoters and 5’ exons. Although they share a common carboxyl terminus, 
E2F3a is expressed in proliferating cells and acts as activating E2F whereas E2F3b is 
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expressed in both quiescent and proliferating cells with a proposed transcriptional 
repressor function (Adams et al., 2000; He et al., 2000; Leone et al., 2000).  Aslanian et 
al has characterized E2F3b as a repressor of mouse Arf transcription by showing elevated 
expression of Arf in E2F3-/- MEFs, together with the detection of direct E2F3 binding on 
Arf locus by using an antibody recognizing both E2F3a and 3b, but not an antibody 
specific for E2F3a (Aslanian et al., 2004).  
 
 
Figure 1.7. Schematic of the E2F3a and E2F3b proteins, and the ChIP 
antibodies used in (Aslanian et al., 2004) . 
 
There is ample evidence suggesting the activating E2Fs as positive regulators of 
Arf expression (Phillips and Vousden, 2001). Overexpression of the activating E2Fs is 
able to trigger increased Arf transcription (DeGregori et al., 1997; Phillips et al., 1999), 
leading to either cellular proliferation or apoptosis (Hiebert et al., 1995; Johnson et al., 
1994; Lukas et al., 1996; Qin et al., 1994; Wu and Levine, 1994). However Arf is not a 
classic E2F-responsive gene, because the consensus E2F-binding sites on Arf promoter 
are dispensable for E2F1- mediated Arf activation , and Arf is not expressed in a cell 
cycle dependent manner, either(Berkovich et al., 2003; Iaquinta et al., 2005; Parisi et al., 
2002). Interestingly, a variant E2F site was found on ARF promoter, which responds to 
ectopic E2F1 expression, inactivation of Rb by E1A or shRNA, but not to 
phosphorylation of Rb though CDK activity (Komori et al., 2005).  
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In normally growing MEFs, E2F3 is the only E2F family member that binds to 
Arf promoter, and this binding persists throughout the whole cell cycle (Iaquinta et al., 
2005).  Under oncogenic stress induced by overexpressing E1A, there is a dramatic 
enrichment of E2F1, 2 and 3a to Arf locus accompanied by a greatly elevated Arf 
expression, indicating a significant role of activating E2Fs in the oncogenic-induced Arf 
activation (Aslanian et al., 2004; Iaquinta et al., 2005).  
 
The ARF/p16 locus is hypermethylated in human tumors 
DNA methylation occurs at the C-5 position of cytosine residue in the context of 
CpG dinucleotides, and the CpG-rich areas, which are often found close to promoter 
region, are called “CpG islands”(Gardiner-Garden and Frommer, 1987). The first 
discovery of hypermethylation in a CpG island of a tumor suppressor gene in human 
cancers was that of Retinoblastoma(Rb) gene in 1989(Greger et al., 1989), but the idea 
that CpG island promoter hypermethylation can be a mechanism of inactivating genes in 
cancer had not got attention until the Von Hippel-Lindau (VHL) gene was also found to 
undergo methylation-associated inactivation(Herman et al., 1994).  In 1995, the 
pioneering discoveries from the laboratories of Dr Stephen Baylin and Peter Jones 
demonstrated that CpG island hypermethylation is a common mechanism of inactivating 
p16 in human cancer (Gonzalez-Zulueta et al., 1995; Herman et al., 1995; Merlo et al., 
1995), providing an alternative mechanism to inactivate p16 in tumorigenesis, and more 
importantly, establishing the basis of current research in cancer epigenetic silencing. 
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Similarly, following the finding of ARF as an alternative tumor suppressor 
encoded by the INK4a/ARF locus (Kamijo et al., 1998; Pomerantz et al., 1998; Quelle et 
al., 1995; Stott et al., 1998; Zhang et al., 1998), the promoter of human ARF was cloned 
and found as a CpG island which can be silenced by DNA methylation(Robertson and 
Jones, 1998). p16 and ARF have different hypermethylation profiles in human cancers: 
p16 is hypermethylated in a broader spectrum of tumors, whereas the hypermethylation 
of ARF is more frequently found in cancer from colon, stomach, uterus and 
kidney(Esteller, 2002; Esteller et al., 2001b; Esteller and Herman, 2002).   
DNA methylation is catalyzed by three DNA methyltransferases, DNMT1, 
DNMT3a and DNMT3b. DNMT1 is primarily responsible for the maintenance of DNA 
methylation by locating to replication foci and restores symmetrically methylated CpGs 
on newly synthesized hemimethylated DNA, whereas DNMT3a and 3b can introduce 
DNA methylation de novo, using unmethylated DNA as a substrate (Leonhardt et al., 
1992; Li et al., 1993; Li et al., 1992; Okano et al., 1999). Genetic study of these three 
methyltransferases by knockout mice shows that they are all essential genes, with the 
earliest lethality seen in Dnmt-/- embryos shortly after gastrulation with a completely 
unmethylated genome; knockout mice with either Dnmt3a or Dnmt3b disruption are 
viable, but those lacking both Dnmt3a and Dnmt3b die at early embryonic stages, as do 
Dnmt1-/- embryos (Li et al., 1992; Okano et al., 1999).  
In contrast to the well-characterized DNA methyltransferases, DNA demethylase 
has not been found yet. Recently a new modified form of nucleoside -- 5-
hydroxymethylcytidine (5hmC) was identified, and is regarded as the “6th” base, in 
addition to the four canonical DNA nucleosides -- dA, dC, dG, dT-- and the“5th” base -- 
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5mC. And the enzyme TET1 has been found responsible for the conversion of 5mC to 
5hmC in an Fe(II) and α-KG dependent manner, raising the possibility that DNA 
demethylation may be a TET1-mediated process(Ito et al., 2010; Kriaucionis and Heintz, 
2009; Munzel et al., 2010; Tahiliani et al., 2009). Whether the 5hmC is an intermediate 
for oxidative DNA demethylation process, or a stable end-product acting as a new 
epigenetic regulator of gene expression is still unknown.  
Despite the elusiveness of DNA demethylase, DNA demethylation drugs have 
been widely-used in basic research and clinic trials. 5-Aza-2’-deoxycitidine (5-Aza-CdR) 
and zebularine are two intensively-used specific inhibitors of DNA methylation. As 
analogs of cytidine, they can incorporate into newly synthesized DNA, then form 
covalent complexes with DNA methyltransferase, therefore leading to depletion of active 
enzyme (Bouchard and Momparler, 1983; Cheng et al., 2003; Santi et al., 1983; Santi et 
al., 1984).  
DNA hypermethylation has been linked with histone deacetylation and 
methylation of histone H3K9 in the silencing of gene expression.  Methylated DNA and 
methy-CpG-binding protein MeCP2 can recruit histone deacetylase (HDAC) to repress 
transcription, and this process can by reversed by HDAC inhibitor trichostatin A 
(TSA)(Eden et al., 1998; Jones et al., 1998; Nan et al., 1998). Furthermore, 
hypermethylation of CpG islands is dominant over deacetylation for the stable 
maintenance of the silent loci (Cameron et al., 1999). DNA demethylation by 5-Aza-CdR 
can induce rapid and substantial remodeling of heterochromatic domains of INK4A/ARF 
locus in tumor cells, characterized by reduced dimethylated H3K9, increased 
dimethylated H3K4 and H3 acetylation (Nguyen et al., 2002).  
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DNA methylation and histone H3K9 methylation contribute to the formation of 
heterochromatine and gene repression 
The two functionally distinct chromatin statuses - heterochromatin and 
euchromatin – are characterized by their specific histone and DNA modifications. 
Trimethylation of histone H3 lysine 4 (H3K4me3) and dimethylation of H3 arginine 17 
(H3R17me2), or acetylation of histone H4 lysine 16 (H4K16ac) are usually associated 
with the transcriptionally active euchromatic loci (Bernstein et al., 2005; Turner, 2000); 
whereas di- or trimethylation of histone H3 lysine 9 (H3K9me2/me3) and methylation of 
DNA are enriched at transcriptionally silenced genes and constitutive heterochromatin 
(Fahrner et al., 2002; Lehnertz et al., 2003; Tariq et al., 2003).  
In mammals, there are 3 functional DNA methyltransferases (Dnmt1, Dnmt3a, 
and Dnmt3b) and at least 5 H3K9 methyltransferases (Suv39h1, Suv39h2, G9A, 
Eset/SETDB1, and EuHMTase). Among the H3K9 methylases, G9A and SETDB1 are 
mainly for mediating the silencing of euchromatic genes, whereas Suv39H1 and 
Suv39H2 are often found to modify H3K9 at constitutive heterochromatin (Stancheva, 
2005). There are close interactions between the functional complexes of DNA 
methylation and H3K9 methylation, plus cooperation with other repressor units. H3K9me 
is able to provide binding sites for heterochromatin-associated chromodomain protein 
(HP1) (Bannister et al., 2001; Lachner et al., 2001). In biochemical assays, all 3 
mammalian DNA methyl transferases associate with H3K9 methyltransferase activities, 
and Dnmt1 and Dnmt3a/3b directly interact with HP1 (Fuks et al., 2003a; Lehnertz et al., 
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2003). Proteins that specifically bind to methylated DNA, such as MeCP2, MDB2, and 
kaiso, were found to be associated with HDAC activity and have properties of HDAC-
dependent transcriptional repressors (Bird and Wolffe, 1999; Jones et al., 1998; Nan et al., 
1998; Ng et al., 1999; Tachibana et al., 2002; Yoon et al., 2003). It was also reported that 
MeCP2 and MBD1, are associated with H3K9-specific histone methylase activities 
(Fujita et al., 2003; Fuks et al., 2003b; Sarraf and Stancheva, 2004).  
The crosstalk and cooperation between DNA methylation and H3K9 methylation 
in the establishment and maintenance of heterochromatin has been intensively 
investigated in various organisms, and it has been found that H3K9 methylation is either 
completely (Neurospora) or partially (Arabidopsis) responsible for DNA methylation 
patterns in the genome (Stancheva, 2005). However, the mechanism in mammals is more 
complicated. MEFs that are double null for Suv39H1 and Suv39H2 display 
hypomethylation of DNA at major satellite repeats, comparable to that observed in 
Dnmt3a/3b double-knockout embryonic stem cells (Lehnertz et al., 2003; Okano et al., 
1999). Together with demonstrated association of Dnmt3b and HP1 in both mouse and 
human cells, these data indicate that the recruitment of DNA methylases to major satellite 
repeats requires pre-existing H3K9 methylation by Suv39H1/2 and binding of HP1 
(Lehnertz et al., 2003). However, this might not apply to all heterochromatic loci, since 
DNA methylation at minor satellite sequences and C-type retroviral (MLV) repeats is not 
affected in Suv39H1 and Suv39H2 double-null MEFs (Lehnertz et al., 2003).  
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Summary 
 
 In the subsequent chapters, I explored several aspects of the transcriptional 
regulation of ARF.  In Chapter 2, modified from a manuscript just finished revision, I 
elucidated the molecular mechanisms by which p53 represses mouse Arf expression. In 
Chapter 3, I extended my research on Arf regulation to human cells and found that human 
and mouse has different systems to repress ARF expression. Following up on the reported 
activation of ARF expression by oncogenic/proliferative stress, in Chapter 4, I carried out 
preliminary studies to characterize the epigenetic events underlying these events.  Finally, 
I summarized and discussed future directions for research on the transcriptional 
regulation of ARF locus. 
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CHAPTER 2 
 
 
P53 BINDS TO AND IS REQUIRED FOR THE REPRESSION OF ARF TUMOR 
SUPPRESSOR BY HDAC AND POLYCOMB   
22 
Summary 
The expression of tumor suppressor Arf is tightly repressed during normal cell 
growth in human and mouse at young age and is activated by oncogenic insults and 
aging, resulting in p53 activation and cell cycle arrest to prevent hyperproliferation. The 
mechanisms of both transcriptional repression and activation of Arf are not understood. In 
this chapter, my data shows that p53 binds to and represses mouse Arf expression and that 
this repression requires the function of both histone deacetylase (HDAC) and polycomb 
group (PcG) proteins. Inactivation of p53 leads to increased Arf transcription in both 
mouse embryonic fibroblasts (MEFs) cultured in vitro and in tissues and organs of p53 
null mice. Activation of endogenous p53 in wild-type MEFs enhances Arf repression, and 
reintroduction of p53 back into p53 null MEFs restores the repression of Arf expression. 
Both DNA binding and trans-activation activities are required for p53-mediated Arf 
repression. Conversely, p53 is required for both HADC and PcG to repress mouse Arf 
expression. Binding of both HDAC and PcG to Arf are disrupted by inactivation of p53 
and can be restored in p53 null MEFs by the reintroduction of wild-type, but not mutant 
p53. These results indicate that p53 recruits both HDAC and PcG to the mouse Arf locus 
to repress its expression, and this repression constitutes a second feedback loop in p53 
regulation.
23 
Background 
The Ink4a/Arf locus, one of the most frequently mutated sites in human cancer, is 
involved in a wide range of tumors, including melanoma, pancreatic adenocarcinoma, 
glioblastoma and non-small cell lung cancer (Kim and Sharpless, 2006). While sharing 
same exon 2 and exon 3, the two gene products encoded by this locus, ARF(also known 
as p19 for mice and p14 for human) and p16(also called INK4a), have no amino acid 
homology (Quelle et al., 1995) and play independent roles in tumor suppression(Gil and 
Peters, 2006). p19Arf, as the de-repressor of p53, associates with Mdm2 to block the 
proteasome-dependent degradation of p53 by Mdm2 (Pomerantz et al., 1998; Zhang and 
Xiong, 2001). Arf is expressed at very low level during embryogenesis or in young 
tissues, but then becomes epigenetically de-repressed with cell aging (Krishnamurthy et 
al., 2004). Under oncogenic stresses in mice, the expression of Arf is activated to induce 
premature senescence or apoptosis, which acts as a defense mechanism against the 
transformation effect of oncogenic signals (Sherr, 2001). Despite the thorough research of 
Arf function, regulation of Arf expression is poorly understood. Several mechanisms, 
including promoter hypermethylation (Esteller et al., 2001a; Melendez et al., 2000; 
Robertson and Jones, 1998), epigenetic silencing by Polycomb Group Proteins (Bernard 
et al., 2005; Bracken et al., 2007a; Dietrich et al., 2007; Gil et al., 2004; Jacobs et al., 
1999a; Scott et al., 2007) and oncogenic activation via Ras-Raf-Dmp1 pathway (Inoue et 
al., 1999; Sreeramaneni et al., 2005)  have been suggested to modulate the expression of 
Arf. Very recently, the newly found H3K27 demethylase Jmjd3 is also indicated to 
participate in activation of Arf in response to oncogenic stress (Agger et al., 2009; 
Barradas et al., 2009). 
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When there are cellular insults such as DNA damage, p53 is activated to induce 
cell cycle arrest or apoptosis as a transcriptional activator to stimulate the expression of 
CDK inhibitors and apoptotic components(Riley et al., 2008). Mdm2, as the major 
inhibitor of p53, inhibits the transcriptional activity of p53 and promotes the 
ubiquitination and degradation of p53, therefore keeping the function of p53 under 
control (Haupt et al., 1997; Kubbutat et al., 1997; Momand et al., 1992). On the other 
side, the function of p53 can be de-repressed by Arf, which associates with Mdm2 and 
blocks the degradation of p53 (Pomerantz et al., 1998; Zhang et al., 1998).  
 
The Arf-Mdm2-p53 pathway is precisely regulated by two feedback loops. To 
shut down p53 after the cell cycle arrest, p53 can bind and activate the promoter of its 
inhibitor MDM2 (Wu et al., 1993a). p53 is also recognized as a repressor of Arf 
expression based on the inversely correlated level of Arf and p53 in different cell lines 
(Harris and Levine, 2005; Kamijo et al., 1998; Robertson and Jones, 1998; Stott et al., 
1998). The molecular mechanism underlying this feedback regulation is not known yet 
and is the focus of this chapter. 
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Experimental Procedures 
 
Cell culture, western analysis and antibodies 
 
Mouse embryonic fibroblasts (MEFs) were cultured in DMEM supplemented with 
10% FBS, while 293T cells were cultured in DMEM supplemented with 10% NCS. Cells 
were lysed with RIPA buffer (50 mM Tris-HCl/pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% 
DOC, 0.1% SDS, 1 mM Na3VO4, 1 mM DTT, 1 mM PMSF, and a cocktail of protease 
inhibitors containing 25 mg/L of leupeptin, 25 mg/L of aprotinin, 150 mg/L of 
benzamidine, and 10 mg/L of trypsin inhibitor). Antibodies to Bmi1 (F6, Upstate), 
Ring1B (ab-3832, Abcam), Suz12 (ab-12073, Abcam), Ezh2 (ab-3748, Abcam), HDAC1 
(ab-7028, Abcam), Acetyl-Histone H4 (06-598, Upstate), p53 (FL-393X, Santa Cruz), 
p19Arf (ab-80, Abcam), mouse p16 (M-156; Santa Cruz), 3m-H3K27 (ab-6002, Abcam), 
E2F3 (sc-878X, Santa Cruz), Tubulin (Ab-2 DM1A, Neomarkers), Normal Mouse IgG 
(Neomarkers), Normal Rabbit IgG (Neomarkers) and Actin (C-11; Santa Cruz) were 
purchased commercially.   
 
Retroviral and adenoviral procedures 
 
The retroviral vector expressing mouse Bmi1 was kindly provided by Dr. Ned 
Sharpless. Human p53 cDNA was cloned into pBabe-puro retrovirus vector, and point 
mutations were made by site-directed mutagenesis and verified by DNA sequencing. 
Retroviruses encoding shRNAs silencing mBmi1, mE2f3, mHdac1, and mHdac2 were 
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constructed by ligating respective oligonucleotides (mBmi1-1, 
GCTTGTCTATTGAGTTCTTTG; mBmi1-2, GGCCCACTACCTTTGAAATAC; 
mBmi1-3, GGGTCATCAGCAACTTCATCT; mE2f3-1, 
GCTCACCAAGAAGTTCATTCA; mE2f3-2, GCACTACGGAGTCCCGATAGT; 
mHdac1, GATCTACCGTCCTCACAAA; mHdac2, 
GCCAAGAAGTCAGAAGCATCA) into a PMKO-puro vector. For retrovirus 
production, pBabe-puro vectors or PMKO-puro vector (4 µg) were co-transfected with 
pCI-VSV and pCI-PGZ (3 µg each) into 293T cells using the calcium phosphate method. 
Transfected cells were incubated at 37°C in DMEM supplemented with 10% newborn 
calf serum for 24hs. The medium was replaced with DMEM supplemented with 2% 
newborn calf serum and incubated for an additional 24hs at 37°C. Viral supernatants 
were collected and filtered through a 0.45-µm syringe filter, supplemented with 10% FBS 
and 5 µg/mL polybrene. Cells were infected with 6~10 mL of the viral supernatant (for 
p100 plate) for 24hs at 37°C and infection was repeated once. E6 retrovirus was produced 
by 293/E6 stable cell line which was cultured in DMEM/10% FBS. To remove 
uninfected cells, MEFs infected with pBabe-based viruses were selected by 2µg/ml 
puromycin for 3 days and MEFs infected with pLXSB-neo based E6 viruses were 
selected with 600 µg/ml G418 for 5 days.   
 
To infect MEFs with adenovirus, adenovirus was mixed with infection medium 
(DMEM + 0.2% FBS) and added to PBS-washed MEFs (500 µl per p60 plate). Infected 
MEFs were incubated at 37°C for 2 hours, slowly tilted every 20-30 minutes, and then 
replaced with fresh DMEM medium containing 10% FBS and pen/strep.    
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Quantitative-RT-PCR 
 
Total RNA was extracted from tissues or MEFs by RNeasy (Qiagen), and 1 µg 
total RNA was primed with Oligo(dT)20 primers (Invitrogen) for cDNA synthesis. The 
cDNA was added to a Q-RT–PCR mixture that contained 1× SYBR Green PCR master 
mix (Applied Biosystems) and 150 nM gene-specific primers. Assays were performed in 
triplicate on a 7900 HT sequence detection system (Applied Biosystems). The PCR 
includes 2-min incubations at 50°C and 10-min at 95°C, followed by 40 cycles, each 
consisting of 15 sec at 95°C and 1 min at 60°C. The expression level of each gene was 
normalized with mRNA amount of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). Specific PCR pairs were as follows: mGapdh, 5’-
GGTGAAGGTCGGTGTGAACG-3’ and 5’-TGTAGACCATGTAGTTGAGG-3'; mArf, 
5’-AGGCTAGAGAGGATCTTGAG-3’ and 5’-TCCTCGCAGTTCGAATCTGC-3’; 
mHoxA9, 5’-ACGGCAGGTATATGCGCT-3’ and 5’-GAACCAGATCTTGACCTGC-
3’; mHoxC13, 5’-TGTCGCACAACGTGAACCTG-3’ and 5’-
CTTCAGCTGCACCTTGGTATAG-3’ ; mp21, 5’-GTGATTGCGATGCGCTCATG-3’ 
and 5’-TCTCTTGCAGAAGACCAATC-3’. mBmi1, 5’-
GTGCCCATTGACAGCGGCGG-3’ and 5’-AAAGATCCCGGAAAGAGCGGC-3’; 
mE2f3, 5’-CCACCACGTCCTGTGCCACC-3’ and 5’-CCAGCCTTCGCTTTGCCGGT-
3’; mHdac1: 5’-GGGGGCCTGCACCATGCAAA-3’ and 5’-
TGCCAGCCCCAATGTCCCGT-3’; mHdac2: 5’-CGGGTGGTTCAGTTGCTGGGG-3’ 
and 5’- AGACGGTCATCACGCGATCTGT-3’. 
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ChIP assay 
 
5X106 MEF cells were treated with 1% formaldehyde for 15 min at room 
temperature, then 0.125 M glycine was added and cells were incubated for an additional 5 
min at room temperature before lysed on ice in a NP-40 lysis buffer (10 mM 
Hepes/pH7.9, 0.5% NP-40, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT and protease 
inhibitor cocktail). After centrifugation, the nuclear pellets were lysed by sonication on 
ice in a nuclear lysis buffer (20 mM Hepes/pH7.9, 25% glycerol, 0.5% NP-40, 0.5% 
Triton X-100, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA and protease inhibitor 
cocktail). After centrifugation at 13,000 rpm for 10 min in a cold room, the nuclear 
lysates were diluted with 2 volumes of dilution buffer (0.01% SDS, 1% Triton X-100, 1.2 
mM EDTA, 167 mM NaCl, 16.7 mM Tris-HCl/pH8.0 and protease inhibitor cocktail). 
Immunoprecipitation was performed with an antibody specific to Bmi1, Ring1B, Suz12, 
Ezh2, HDAC1, acetyl-Histone H4, p53, 3m-H3K27 and normal rabbit IgG as a control 
for 6hs or overnight at 4ºC. After immunoprecipitation, 20l salmon sperm DNA/protein 
G agarose (Upstate) were added and incubated for another 1h. Precipitates were 
sequentially washed with TSE I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM 
NaCl, 20 mM Tris-HCl/pH 8.1), TSE II (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 
mM NaCl, 20 mM Tris-HCl/pH 8.1), TSE III (0.25 M LiCl, 1% NP-40, 1% 
deoxycholate, 1 mM EDTA, 10 mM Tris-HCl/pH 8.1), and washed twice with TE buffer 
before eluted with 1% SDS and 0.1 M NaHCO3. The elutes were incubated at 65ºC for at 
least 6 hr to reverse the formaldehyde cross-linking. DNA fragments were purified by 
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using PCR purification Kit (Qiagen). PCR was performed using Platinum Taq 
polymerase (Invitrogen) and following pairs of primers: mArf-a, 5’-
ACTCAGGGAGCCCTCAAAAC-3’ and 5’-CAATCCACAGCAGGGTGAC-3’; mArf-
b, 5’-GCCCTCAAACTCAAAGATCC-3’ and 5’-CAAACGCACATATCACAAAGC-
3’; mArf-c, 5’-CAGCTGCTCTTCTTCCTCTCC-3’ and 5’-
TAACGGCGGAGCTTACTTTG-3’; mp16, 5’-CGAACTCGAGGAGAGCCATC-3’ and 
5’-ACACTCCTTGCCTACCTGAA-3’; mGdpdh, 5’-CCCACTTGCCTCTGTATTGG-3’ 
and 5’-CTGTGGGGAGTCCTTTTCAG-3’. For ChIP-Q-PCR, purified DNA was added 
to a Q-RT–PCR mixture that contained 1× SYBR Green PCR master mix and 150 nM 
gene-specific primers. Assays were performed in triplicate on a 7900 HT sequence 
detection system. Following primers were used for Q-PCR of mouse Arf locus: mArf-A, 
5’-GATGCTCGCGCTTAAAACC-3’ and 5’-ACAGCGCGCAGAGAAGAG-3’; mArf-
B, 5’-GCAGCGGCTCTTCTCTGC-3’ and 5’-CCTTGCTCCGAGTCCATC-3’; mArf-C, 
5’-AAACTCAAAGATCCACCTCTGC-3’ and 5’-GCCTAGGGTCCAGTGAATGC-3’. 
 
IP-Western 
WT MEFs cells from one 150-mm plates were lysed with 0.5% NP-40 lysis buffer 
(50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 0.5% NaCl, 50 mM NaF) and clarified 
lysates were incubated with anti-FLAG (2ug), or anti-HDAC1 (2ug), or rabbit IgG(2ug) 
and immunocomplexes were precipitated by Protein-G agarose beads. Eluted 
immunocomplexes were resolved by SDS-PAGE gel detected by western blot.  
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Results 
 
p53 represses Arf expression in vivo 
 
Confirming previous observations (Kamijo et al., 1998; Zindy et al., 1998), the 
steady state level of Arf protein is significantly increased in p53-deficient mouse embryo 
fibroblasts (MEFs, Figure 2.1A). I also observed a clear increase of p16 protein level in 
p53-/- MEFs, which could be caused by the decrease of p21 expression and then a 
reduction in function of Rb pathway which collaborates with Polycomb Repressive 
Complex (PRC) to repress p16 gene transcription in a feedback loop (Kotake et al., 
2007a). Thus far nearly all studies on Arf repression by p53 were carried out in cultured 
MEF or other established cells. A demonstration of Arf repression by p53 in vivo has 
been lacking. Therefore, I dissected three pairs of age-matched (one pair of littermates at 
age of 5-week and two at age of 8-week) wild-type and p53 null mice and determined the 
Arf expression in 8 different organs/tissues. This study demonstrated that Arf expression 
was significantly increased by the p53 loss in 4 organs (muscle, kidney, heart and lung), 
moderately in two (liver and spleen) and unchanged in two (thymus and testis) (Figure 
2.1B). This result provides the first evidence demonstrating p53-dependent repression of 
Arf in vivo.  
 
To exclude the possibility that Arf accumulation in p53-null MEFs was caused 
indirectly by other potential mutations and/or adaptive changes accumulated during 
multiple rounds of cell division, I transduced wild-type MEFs with a retrovirus 
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expressing the type 16 papilloma virus-encoded E6 oncoprotein that binds to and targets 
the degradation of p53. Ectopic expression of E6 resulted in a detectable increase of Arf 
protein and mRNA as early as 2 days after viral transduction and a continual increase of 
Arf (Figure 2.1C). This result supports a direct role of p53 in the repression of Arf 
transcription and also suggests a continuous need of p53 to maintain the repression. 
 
Nutlins are a group of small compounds that can bind MDM2 in the p53-binding 
pocket and disrupt the interaction between p53 and Mdm2, thereby activating p53 in vivo 
by releasing it from inhibition by Mdm2 (Vassilev et al., 2004). To provide further 
evidence supporting p53-mediated repression of Arf in vivo, I treated wild-type MEFs at 
passage 2 with Nutlin-3 (10 µM) or solvent DMSO during a course of 24hs and then 
examined Arf expression. Confirming the activation of p53, Nutlin-3 increased p21 
mRNA, an established target of p53 activation, in wild-type MEFs, but had no effect on 
p21 level in p53-/- MEFs. Releasing p53 from the Mdm2-p53 complex by Nutlin-3 
enhanced the repression of Arf transcription in wild-type MEFs within 24hs, resulting in a 
time-dependent decrease of Arf expression by 60% (Figure 2.1D). In contrast, Nutlin-3 
treatment had no effect on Arf level in p53-/- MEFs despite the much higher Arf 
transcription in the cells. From these results, I conclude that p53 represses Arf at a level 
of transcriptional regulation through a mechanism that requires a direct and continuous 
role of p53 
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Figure 2.1 
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Figure. 2.1.  p53 represses Arf expression in vivo 
(A) The steady state levels of Arf and p16 proteins were determined in wild-type (WT) 
MEFs and p53-/- MEFs at passage 5 by immunoblotting.  
 
(B) 3 pairs of age-matched wild-type and p53-/- mice were dissected and total RNA was 
extracted from 8 different organ/tissues. The level of Arf mRNA was determined by Q-
RT-PCR and data were expressed relative to the corresponding values of wild-type 
tissues. Mean values and standard deviations were calculated from triplicates of 3 
different repeats.  
 
(C) WT MEFs (passage 2) were infected with an empty (mock) or E6-expessing 
retrovirus and selected by G418 treatment. Cells were collected at indicated time after 
infection. The levels of p53 and Arf proteins or mRNA were determined by 
immunoblotting or quantitative real-time reverse transcriptase PCR (Q-RT-PCR), 
respectively. Data were expressed relative to the corresponding values of mock cells and 
mean value and standard deviations were calculated from triplicates of 3 independent 
repeats.  
 
(D) WT (passage 2) and p53-/- MEFs were treated with 1% DMSO or 10 µM Nutlin3 and 
were collected at indicated time. The levels of Arf and p21 mRNA were determined by 
Q-RT-PCR. Data were expressed relative to the corresponding values of DMSO-treated 
cells and mean value and standard deviations were calculated from triplicates of 3 
independent repeats. 
 
 
p53 binds directly to Arf  
 
That p53 is directly involved in Arf repression led me to determine whether p53 
binds to the Arf locus. To identify the specific p53 binding sites on the Arf locus, I used a 
panel of 35 pairs of oligonucleotide primers and searched a region spanning 4kb upstream 
and 4kb downstream of the transcription start site of mouse Arf. I detected a direct p53 
binding to a region immediately upstream and downstream of exon1β (a, b, c) of Arf 
(Figure 2.2A). In contrast, there was very little binding of p53 to the p16 promoter I 
examined nor any p53 binding detected by using p53-/- MEF as negative control in ChIP 
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analysis.. These results support the observation that p53 affects the expression of Arf and 
p16 differently and suggest a direct role of p53 in the repression of Arf expression.  
 
p53 mediated repression of Arf needs both transactivation and DNA binding activity  
 
To provide further evidence supporting a direct role of p53 in Arf repression, I 
examined four p53 mutants in Arf repression, including two well-characterized p53 hot-
spot mutants—R175H, which grossly disrupts p53’s protein conformation and R273H, 
which retains p53’s native conformation but loses contact with DNA [see a recent review 
on the genetic and biochemical properties of different p53 mutants (Lozano, 2007)]. In 
addition, I also examined a double mutant—L22Q/W23S—which disrupts p53’s 
transcriptional activity as well as the binding with Mdm2 (Lin et al., 1994) and a 
hyperactive p53 mutant—H178Y—that could rescue the inactivated function of a 
common mutation G245S (Otsuka et al., 2007). p53-/- MEFs were transduced with a 
retrovirus expressing the wild-type and individual mutants of p53 and their expressions 
were verified by direct immunoblotting (Figure 2.2B). As expected, the three functional 
inactivation mutants—p53L22Q/W23S, p53R175H and p53R273H—were expressed at 
high levels, whereas cells can only tolerate a much lower level expression of both wild-
type p53 and hyperactive p53H178Y mutant. The activity of the wild-type and individual 
mutant p53 was functionally verified by examining the expression of p21 (Figure 2.2D). 
While both wild-type and p53H178Y mutant increased p21 mRNA levels, the three 
functional inactivation mutants had little effect on p21 mRNA level.  
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As determined by ChIP and quantitative RT-PCR assay, p53H178Y bound to Arf 
stronger than the wild-type p53 and p53L22Q/W23S exhibited decreased Arf binding. 
Both p53R175H and p53R273H, however, bound very weakly to Arf (Figure 2.2C). I 
then determined the ability of these p53 mutants to restore Arf repression in p53 null 
MEFs. Starting 5 days after viral transduction, both wild-type and the hyperactive 
p53H178Y mutant reduced the Arf mRNA level by 50% (Figure 2.2D). In contrast, 
ectopic expression of p53L22Q/W23S, p53R175H and p53R273H at very high levels had 
little effect in restoring the repression of Arf. Together, these results demonstrate that p53 
represses Arf by directly binding to the Arf locus and that both transactivity and DNA 
binding of p53 are essential to repress Arf expression.  
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Figure. 2.2. Both transactivation and DNA binding activity of p53 are required for 
p53 to bind and repress Arf 
(A) WT MEFs and p53-/- MEFs (passage 2) were analyzed for p53 binding on Arf and 
p16 locus. The amount of DNA immunoprecipitated by p53 or rabbit IgG were expressed 
relative to the percentage of input DNA, and mean values and standard deviations were 
calculated from triplicates of 2 independent repeats.  
 
(B) p53-/- MEFs were infected with an empty retrovirus (mock) or retrovirus expressing 
wild-type p53 and mutant p53. Cells were selected by puromycin treatment, collected at 
indicated time after infection and the expression levels of p53 were determined by 
immunoblotting.  
 
(C) Cells in (B) collected 8 days after infection were analyzed for binding of p53 on Arf 
locus by ChIP-Q-PCR. The mean values were calculated from triplicates of a 
representative experiment.  
 
(D) p21 mRNA levels of cells in (B) were determined 2 days after infection by Q-RT-
PCR, and cells collected at different times after infection were analyzed for Arf mRNA 
levels by Q-RT-PCR. The mean values and standard deviations were calculated from 
triplicates of 4 independent repeats. 
 
 
HDAC binds to and represses Arf and is recruited to mArf in a p53-dependent 
manner 
 
Histone deacetylases (HDACs) associate with many transcriptional repressive 
complexes and have also been reported to participate in the transcriptional repression of 
both human and mouse ARF genes (Matheu et al., 2005; Yarosh et al., 2008). To 
determine whether HDACs are involved in p53-mediated repression of Arf transcription, 
we first confirmed the involvement of HDAC in the repression of Arf by treating human 
WI38 cells or wild-type MEFs with TSA, an inhibitor of class I/II HDACs. We found that 
a low concentration of TSA (0.1 µM) increased mouse Arf mRNA level by >15-fold 
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within 24hs (Figure 2.3A). To confirm the repression of mouse Arf by HDACs, I carried 
out a time course experiment and found that treatment of wild-type MEFs with TSA (0.1 
µM) resulted in detectable Arf protein increase as early as 6 hours, peaking around 25 
hours and lasting to as long as 60 hours (Figure 2.3B). These results demonstrate a potent 
role of HDACs in the repression of mouse Arf transcription.  
 
To further determine the role of HDAC in repressing Arf, I tested the binding of 
HDAC1 on Arf in wild-type MEFs. ChIP assay showed that HDAC1 directly binds to a 
region immediately upstream of the transcription starting site of Arf, whereas no binding 
of HDAC1 was detected on the nearby p16 locus (Figure 2.3C). Importantly, the binding 
of HDAC1 to mouse Arf was greatly decreased, by more than 60% (for amplicon A) to 
80% (amplicon B), in p53-/- MEFs (Figure 2.3D), providing the first evidence linking 
HDAC-mediated repression of Arf transcription to the function of p53. Supporting a 
functional dependency of deacetylation of Arf promoter on p53 function, activation of 
p53 by Nutlin-3 in wild-type MEFs resulted in a 6-fold increase of HDAC1 binding to 
Arf (Figure 2.3E) and reintroduction of wild-type p53, but not p53L22Q/W23S and 
p53R273H, back into p53-/- MEFs restored the binding of HDAC1 to the Arf locus 
(Figure 2.3F). Finally, I showed that H4 acetylation of the Arf promoter in p53-/- MEFs 
was 2-fold higher than that in wild-type MEFs (Figure 2.3G). Together, these results 
demonstrate that HDAC1 directly binds to and deacetylates Arf in a p53-dependent 
manner.   
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Figure. 2.3. HDAC1 binds to and represses Arf in a p53-dependent manner 
(A) Human WI38 cells and WT MEFs at passage 3 were treated with 1µM TSA for either 
12hs or 24hs. The levels of Arf protein or mRNA were determined by immunoblotting or 
Q-RT-PCR. The mean value and standard deviations were calculated from triplicates of 3 
independent repeats.  
 
(B) WT MEFs at passage 3 were treated with 0.1µM TSA for 0~72hs. Cell pellets were 
collected at indicated time point and steady state level of protein was determined by 
immunoblotting.  
 
(C) Binding of HDAC1 to Arf locus was examined in WT MEFs at passage 2 by ChIP 
analysis. PCR and ChIP-Q-PCR were carried out using indicated primers. The amount of 
DNA immunoprecipitated by HDAC1 or rabbit IgG were expressed relative to the 
percentage of input DNA, and mean values and standard deviations were calculated from 
triplicates of 2 independent repeats.  
 
(D, G) Binding of HDAC1 on Arf, and amount of acetylated histone H4 on Arf were 
quantified in WT and p53-/- MEFs by ChIP-Q-PCR. The data were expressed relative to 
the corresponding values for wild-type MEFs and mean value and standard deviations 
were calculated from triplicates of two independent repeats.  
 
(E) Wild-type MEFs at passage 3 were treated with 1% DMSO or 10µM Nutlin-3 and 
cells were collected after 16hs. The binding of HDAC1 on Arf was determined by ChIP-
Q-PCR with indicated primers. Data were expressed relative to the corresponding values 
of DMSO-treated cells and mean value and standard deviations were calculated from 
triplicates of three independent repeats.  
 
(F) p53-/- MEFs were infected with an empty retrovirus (mock) or retrovirus expressing 
WT and mutant p53. Cells were selected by puromycin treatment and collected at 5 days 
after infection. Binding of HDAC1 to Arf was analyzed by ChIP-Q-PCR using Arf 
amplicon A. The mean value and standard deviation were calculated from triplicates of 3 
independent repeats. 
 
 
p53 is required for polycomb repressive complex to bind and repress Arf 
 
Previous studies have shown that oncogene Bmi1 promotes cell proliferation and 
extends the life span of fibroblasts in part through repressing both p16Ink4a and p19Arf 
expression (Jacobs et al., 1999a; Jacobs et al., 1999b). More recently, polycomb group 
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proteins have been shown to directly bind and repress both p16 and ARF in mouse cells 
(Bracken et al., 2007b; Kotake et al., 2007a). To determine the functional interplay 
between p53 and PcG in repressing Arf expression, I transduced both wild-type and p53-
/- MEFs with a retrovirus expressing the Bmi1 gene and determined Arf expression. Nine 
days after retrovirus transduction (passage 5), both the steady state level of the Arf protein 
and mRNA were decreased substantially in Bmi1-overexpressing wild-type MEFs 
compared to the mock-virus infected cells (Figure 2.4A). In contrast, although Arf is 
expressed at a much higher level in p53-/- MEFs, overexpression of Bmi1 did not have 
any significant effect to either Arf protein or mRNA level. To determine the specificity of 
the functional dependency of Bmi1-mediated repression of Arf on p53, I examined the 
expression of two classical Bmi1 repressive targets—HoxA9 and HoxC13 (Cao et al., 
2005b)—in the wild-type and p53-/- MEFs. I found that ectopic expression of Bmi1 was 
capable of repressing the transcription of both HoxA9 and HoxC13 genes regardless of 
the p53 status with a slightly, but reproducible, more repressive effect in p53 null MEFs 
(Figure 2.4B). Together, these results demonstrate a specific functional dependency of 
Bmi1-mediated repression of Arf transcription on p53.  
Bracken et al have previously found that PRC, in the case of repressing p16, can 
also bind directly to the mouse Arf locus to repress its expression (Bracken et al., 2007b). 
To search for the mechanism of the p53-dependency of Arf repression by Bmi1, I 
examined by ChIP assay the binding of Bmi1 and Ring1B, another component of the 
Polycomb Repressive Complex (PRC), to the Arf locus in wild-type and p53-/- MEFs. I 
confirmed the binding of both Bmi1 and Ring1B to the Arf locus. Notably, the bindings 
of both Bmi1 and Ring1B to the Arf locus were greatly decreased in p53-/- MEFs (Figure 
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2.4C). Confirming the p53-dependency, binding of Ring1B to the Arf locus in wild-type 
MEFs was also greatly reduced after transduction with an E6-expressing retrovirus 
(Figure 2.4D). Consistent with the continuous de-repression of Arf during in vitro 
culturing, the binding of Ring1B was also decreased as MEFs aged and become almost 
undetectable after passage 4 (lane 1, Figure 2.4D). Conversely, the binding of Ring1B on 
Arf was increased in wild-type MEF when p53 was activated by Nutlin-3 (Figure 2.4E). 
Together these results demonstrate a requirement of p53 for the binding of PRC1 to Arf 
locus.  
Previous studies on Hox gene silencing by PRC suggest a sequential model 
whereby PRC2-mediated H3K27 trimethylation facilitates the recruitment of PRC1, 
which causes H2A-K119 ubiquitylation to repress Hox gene expression (Cao et al., 
2005a; Wang et al., 2004b). I therefore further analyzed the binding of PRC2 and H3K27 
trimethylation on Arf. Quantification of H3K27 trimethylation on Arf showed a dramatic 
decrease of this repressive marker in p53-/- MEFs to less than 7% in comparison with 
wild-type MEFs (Figure 2.4F). Likewise, the binding of two components of PRC2, Ezh2 
and Suz12, to the Arf locus were also substantially reduced in p53-/- MEFs to 29% and 
6.7% for Ezh2 and to 43% and 18% for Suz12 of that seen in the wild-type MEFs at sites 
A and C, respectively (Figure 2.4F). Hence, the function of p53 is required for both PRC1 
and PRC2 to bind to the Arf locus.  
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Figure. 2.4. p53 is required for PRC to bind and repress Arf  
(A, B) WT MEFs at passage 2 and p53-/- MEFs were infected with empty (mock) or 
Bmi1-expressing retrovirus. 9 days after infection, MEFs were collected and lysed by 
RIPA buffer. The protein levels of Bmi1 and Arf were determined by immunoblotting; 
the mRNA levels of Arf (A), HoxA9, and HoxC13 (B) were determined by Q-RT-PCR. 
Q-RT-PCR results were expressed relative to the corresponding values for mock cells and 
mean value and standard deviations were calculated from triplicates of 3 independent 
repeats.  
 
(C) Binding of Bmi1 and Ring1B to Arf locus were tested in wild-type MEFs at passage 2 
and p53-/- MEFs by ChIP analysis. Antibodies against mouse Bmi1, mouse Ring1B, and 
IgG control were used in the Immunoprocipitation. PCR was carried out using indicated 
primers with GAPDH as a negative control.  
 
(D) WT MEFs at passage 2 were infected with an empty retrovirus (mock) or E6 
retrovirus and selected by G418 treatment. Cells were collected at indicated time after 
infection and analyzed for Ring1B binding on Arf. ChIP-Q-PCR data were expressed 
relative to the corresponding values for mock cells and mean value and standard 
deviations were calculated from triplicates of 3 independent repeats.  
 
(E) Wild-type MEFs at passage 3 were treated with 1% DMSO or 10µM Nutlin3 and 
cells were collected after 16hs. The binding of Ring1B on Arf was determined by ChIP-
Q-PCR with indicated primers. Data were expressed relative to the corresponding values 
of DMSO-treated cells and mean value and standard deviations were calculated from 
triplicates of a representative experiment.  
 
(F) ChIP-Q-PCR was used to determine the trimethylation of H3K27 and binding of Ezh2 
and Suz12 on Arf locus in WT MEFs (passage 3) and p53-/- MEFs. The mean values and 
standard deviations were calculated from triplicates of 3 independent repeats.   
 
 
Both transactivity and DNA binding activities of p53 are required for PRC1 binding 
to Arf 
 
To further demonstrate the requirement of p53 in facilitating the binding of PRC1 
to the Arf locus, we re-introduced p53 back into p53-/- MEFs. Arf is expressed at a very 
low level in wild-type MEFs and was not significantly reduced by the ectopic expression 
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of additional p53. In contrast, re-introducing p53 by either adenovirus or retrovirus into 
p53-/- MEFs partially restored the repression of both Arf protein and mRNA (Figure 
2.5A and 2.5B). The binding of Ring1B to Arf was also restored when p53 was 
ectopically expressed, resulting in a 2- to 3-fold and 4- to 7-fold increase of Ring1B 
binding to Arf in p53-/- MEFs after adenovirus- and retrovirus-mediated p53 expression, 
respectively (Figure 2.5A and 2.5B). This result provides additional evidence supporting 
an essential role of p53 in recruiting PRC to the Arf locus.  
 
I then determined the ability of mutant p53 in restoring PcG binding to Arf by 
ChIP analysis. Both wild-type p53 and the hyperactive p53H178Y mutant restored 
Ring1B binding to Arf, leading to a 2.4-fold and 1.9-fold increase of Ring1B binding, 
respectively (Figure 2.5C). In contrast, none of the three inactivation mutants of p53—
p53L22Q/W23S, p53R175H and p53R273H—showed any effect in restoring Ring1B 
binding to Arf locus. Together these results demonstrate that both the trans-activating and 
DNA binding activities of p53 are required for the binding of PcG to Arf.  
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Figure. 2.5. Both transactivity and DNA binding activity of p53 are required for 
PRC1 binding to Arf 
(A) WT (passage 3) and p53-/- MEFs were infected with either GFP- or p53-expressing 
adenovirus. Two days after infection, cell lysates were analyzed by western blot for 
expression of p53 and Arf, and crosslinked cell pellets were collected and analyzed for 
binding of p53 and Ring1B to Arf locus. ChIP-Q-PCR data were expressed relative to 
corresponding values of Ad-GFP infected MEFs, and mean values and standard 
deviations were calculated from triplicates of a representative repeats.  
 
(B) p53-/- MEFs were infected with either an empty (mock) or p53-expressing retrovirus, 
selected by puromycin treatment and collected at indicated days after infection. The 
levels of p53 and Arf proteins or mRNA were determined by immunoblotting or Q-RT-
PCR. Cells collected at 5 day after infection were analyzed for p53 and Ring1B binding 
on Arf by ChIP-Q-PCR. The mean value and standard deviations were calculated from 
triplicates of 3 independent repeats.  
 
(C) p53-/- MEFs were infected with either an empty retrovirus (mock) or retrovirus 
expressing wild-type or mutant p53. Cells were selected by puromycin treatment and 
collected at 8 days after infection. Bindings of Ring1B to Arf were analyzed by ChIP-Q-
PCR using Arf amplicon B. The mean values and standard deviations were calculated 
from triplicates of a representative experiment.  
 
 
HDAC function is required for PcG to bind mouse Arf 
 
Given that p53 is required for the binding of both HDAC and PcG complexes to 
the Arf locus and that HDAC has been reported to be in the same repressive complex with 
and facilitate the repressive function of PcG (Tie et al., 2001; van der Vlag and Otte, 
1999), I next determined the requirement of HDAC function for PcG binding on Arf by 
two different approaches, pharmacological inhibition of HDAC activity and shRNA-
mediated depletion of HDACs. I first treated wild-type MEFs with TSA and found that 
this treatment did not affect the steady state level of the Ring1B protein, but substantially 
decreased Ring1B binding to Arf (Figure 2.6A). Treatment of cells with a different 
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pharmacological inhibitor of HDAC, sodium butyrate (NaB), increased Arf expression as 
significantly as TSA (Figure 2.6B). Inhibition of HDAC by either TSA or NaB increased 
H4 acetylation, decreased Ring1B binding and H3K27 tri-methylation on Arf promoter 
(Figure 2.6C).  
 
To further demonstrate the requirement of HDAC for PcG binding, I used shRNA 
to knock down HDAC1 and HDAC2 in WT MEFs. Although only a partial depletion was 
achieved, I already observed a decrease of Bmil1 binding to Arf and a clear increase of 
Arf expression (Figure 2.6D). These results demonstrate that the activity of HDAC is 
required for PcG to bind to and repress the expression of Arf and both HDAC1 and 
HDAC2 contribute to this inhibition.   
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Figure 2.6. HDAC function is required for PRC to bind Arf  
(A) Wild-type MEFs at passage 3 were treated with 0.1 µM TSA for 24hs. Cell pellets 
were collected and analyzed for protein levels by immunoblotting and binding of Ring1B 
on Arf by ChIP. ChIP-Q-PCR data were expressed relative to the corresponding values 
for untreated cells and mean value and standard deviations were calculated from 
triplicates of 3 independent repeats.  
 
(B) Wild-type MEFs at passage 3 were treated with 0.1µM TSA or 10mM NaB for 30hs 
and cells were collected and analyzed for Arf mRNA amount by Q-RT-PCR. Mean 
values were calculated from triplicates of a representative experiment.  
 
(C) Cells in (B) were collected and analyzed for histone H4 acetylation, histone H3K27 
trimethylation and Ring1B binding on Arf locus by ChIP-Q-PCR. Data were expressed 
relative to the corresponding values for untreated cells and mean values and standard 
deviations were calculated from triplicates of 2 independent repeats.  
 
(D) WT MEFs were infected with either an empty (mock) or shHDAC-expressing 
retovirus,selected by puromycin for 2 days and collected 4 days after infection. The 
mRNA levels of HDAC1, HDAC2 and Arf were determined by Q-RT-PCR, and the 
binding of Bmi1 to Arf locus were determined by ChIP-Q-PCR. Mean values were 
calculated from triplicates of a representative experiment.  
 
 
HDAC and PcG function are required for p53 to repress Arf expression 
 
The demonstration of functional dependency of both HDAC and PcG on p53 in 
the repression of Arf expression led us to determine conversely whether these two histone 
modifying enzymes are required for p53 to repress Arf expression. To determine whether 
the function of HDAC is required for p53-mediated Arf repression, I inhibited 
endogenous HDAC with TSA in wild-type MEFs and then determined whether activation 
of endogenous p53 by Nutlin can still repress Arf. As shown in Figure 2.7A, while 
activation of p53 by Nutlin-3 resulted > 50% decrease of Arf expression in control MEFs, 
it had no detectable effect on Arf expression when the HDACs were inhibited by TSA 
51 
even though the Arf mRNA level was elevated by as much as more than 16 folds in the 
TSA-treated cells. As a control for p53 activation, inhibition of HDACs by TSA did not 
affect the increase of p21 expression by Nutlin-activated p53.  
 
To determine whether the function of PcG is required for p53 to repress Arf 
expression, I knocked down the expression of Bmi1 by three different shRNAs in wild-
type MEFs and examined the effect of Bmi1 silencing on Arf repression by Nutlin-
activated p53. All three shBmi1 viruses efficiently reduced the expression of Bmi1 
(Figure 2.7B) and none of them affected the activation of p21 expression by Nutlin-
activated p53. While activation of p53 by Nutlin-3 effectively reduced Arf expression by 
more than 50% in wild-type MEFs infected with mock virus, it had no significant effect 
to reduce Arf expression in MEFs cells transduced with any of the three shRNA virus 
targeting Bmi1. Hence, the function of p53 in the repression of Arf expression is also 
dependent on PcG.   
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Figure 2.7. HDAC and PcG function are required for p53 to repress Arf.   
(A) Wt MEFs at passage 2 were treated with TSA and Nutlin-3 either alone or in 
combination for 24hs. Cells were collected and analyzed for mRNA levels of p21 and Arf 
by Q-RT-PCR. Data were expressed relative to the corresponding value of control cells 
with neither TSA nor Nutlin-3 treatment. Mean values and standard deviations were 
calculted from triplicates of a representative experiment.  
 
(B) Wt MEFs (passage 2) were infected with either an empty (mock) or shBmi1-
expressing retrovirus, selected by 2 µM puromycin for 2 days, continusly cultured for 5 
days after infection and then treated with Nutlin-3 for 24hs. Cells were collected and 
analyzed for Bmi1, p21 and Arf mRNA level by Q-RT-PCR. Data were expressed 
relative to the corresponding values of mock-infected cells without Nutlin-3 treatment, 
and mean values and standard deviations were calculated from triplicates of a 
representative experiment.  
 
 
P53 binds with HDAC1 in vivo 
A p53-HDAC binding has previously been reported (Murphy et al. 1999, Genes & 
Dev. 13:2490). And I repeated this finding by retrovirally transducing WT MEFs with 
p53, then determined the binding between p53 and endogenous HDAC1 by IP-Western. 
p53 was detected in HDAC1-immunoprecipitaed complex and HDAC1 was also found in 
the p53 - immunoprecipitates (Figure 2.8). This data further support the recruitment of 
HDAC1 by p53 to mouse Arf locus.  
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Figure 2.8 
 
 
Figure 2.8. p53 binds to HDAC1 in vivo.   
Wt MEFs at passage 2 were infected by either an empty (mock) or FLAG3-p53-
expressing retrovirus for 3 days. Then cells were lysed with 0.5% NP-40 buffers and 
association between p53 and HDAC1 were analyzed by IP-western. 
 
 
p53 and E2F3 repressed Arf expression via independent pathways 
 
E2F3 has been previously reported to repress Arf expression in MEF by Jackie 
Lee’s lab (Aslanian et al. 2004, Genes & Dev. 18:1413). To explore whether p53 and 
E2F3 functionally interact with each other in the repression of mouse Arf, I first 
confirmed the binding of E2F3 to Arf locus in WT MEF (Figure 2.9A). Then I tested 
E2F3 binding on Arf locus in both WT and p53-/- MEFs and found that p53 is not 
required for E2F3 to bind mouse Arf locus.  
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Conversely, I knocked down E2F3 with two different shRNA retroviruses, and 
tested whether reintroducing p53 to p53-/- MEFs could still repress Arf expression after 
E2F3 depletion. I found that reduction of E2F3 had no detectable effect on p53-mediated 
Arf repression (Figure 2.9B). Therefore p53 and E2F3 repress Arf expression by two 
independent mechanisms.   
 
Figure 2.9 
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Figure 2.9. p53 and E2F3 repressed Arf expression via independent pathways.   
 (A) Binding of E2F3 to Arf locus was examined in WT MEFs and p53-/- MEFs at 
passage 3 by ChIP analysis. ChIP-Q-PCR were carried out using following primers 1-5 
on Arf promoter: mArf-1: 5’-GATGCTCGCGCTTAAAACC-3’ and 5’-
ACAGCGCGCAGAGAAGAG-3’; mArf-2: 5’- GCAGCGGCTCTTCTCTGC-3’ and 5’-
CCTTGCTCCGAGTCCATC-3’; mArf-3: 5’-CAGCTGTCACCCTGCTGTG-3’ and 5’-
TGAGAAAGCGGGAAGTCAAG-3’; mArf-4: 5’-TCTCACCTCGCTTGTCACAG-3’ 
and 5’-AGGGCCTTTCCTACCTGGTC-3’; mArf-5: 5’-GCTGGCTGTCACCGCGAT-3’ 
and 5’-GCGTTGAGGCACCTCGAGA-3’. The amount of DNA immunoprecipitated by 
E2F3 or rabbit IgG were expressed relative to the percentage of input DNA, and mean 
values and standard deviations were calculated from triplicates of a representative 
experiment.  
 
(B) p53-/- MEFs at passage 5 were infected by either an empty (mock) or shE2F3-
expressing retrovirus and selected with 2 uM puromycin for 2 days. Then the E2F3-
depleted stable cell lines were infected with either GFP- or p53-expressing adenovirus. 
2.5 days after adenoviral infection, cell pellets were collected and analyzed for E2F3 and 
Arf mRNA level by Q-RT-PCR. Data were expressed relative to the corresponding 
values of mock/GFP-infected cells, and mean and standard deviations were calculated 
from triplicates of 2 independent repeats. 
 
Discussion 
 
The results presented here demonstrate a direct role of p53 in the repression of 
mouse Arf transcription by showing the direct binding of p53 to the mouse Arf locus and 
the requirement of p53 for recruiting HDAC and PcG proteins to the Arf locus. My 
results are consistent with a model where p53 binds specifically to the Arf locus and then 
recruits histone deacetylases to deacetylate the Arf locus. Deacetylation of the Arf locus 
then facilitates the recruitment of PRC to the Arf locus, leading to H3K27 trimethylation 
and silencing of Arf expression. This model is supported by three lines of evidence. First, 
I showed that Arf expression is elevated in vivo in multiple p53-deficient tissues or 
organs, is rapidly elevated upon functional inactivation of p53 and is further repressed 
upon the activation of endogenous p53 in early passage of wild-type MEFs. Second, I 
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demonstrated that p53 directly binds to Arf locus, and that both transactivation and DNA 
binding activities of p53 are required for the repression of Arf and, importantly, for the 
binding to and repression of Arf by both HDAC and PRC. Thirdly, I have also shown that 
both HDAC and PcG are conversely required for p53 to repress Arf expression. E2F3 has 
been previously reported to repress Arf expression in MEF (Aslanian et al., 2004). I found 
that the binding of E2F3 to Arf was not detectably affected by the p53 loss and 
conversely, knocking down E2F3 had no significant effect on p53-mediated Arf 
repression (Figure. 2.9), indicating that p53 represses Arf independently from E2F3.  
 
The findings presented here shed mechanistic insights on p53-mediated oncogenic 
checkpoint pathway, one on the mechanism of Arf activation and the other on the 
feedback regulation of p53. Although it has been observed since more than a decade ago 
that many hyperproliferative oncogenes can activate Arf expression (Sherr, 1998), the 
molecular mechanism underlying oncogenic activation of Arf is not known. Our 
demonstration that Arf is bound and repressed by p53 during normal cell growth suggests 
a critical step—dissociating p53 from the Arf locus—for an oncogene to activate Arf 
expression. It will be interesting to determine how an oncogene causes p53 dissociation 
in the presence of increased level of p53 since Arf activation would lead to p53 
stabilization.  
 
Feedback inhibition is a regulatory strategy commonly used in biochemical 
reactions such as the inhibition of threonine dehydrase by isoleucine (Umbarger, 1956). 
The accumulation of an end-product inhibits the enzyme involved in its synthesis to avoid 
58 
excessive accumulation and waste of resources. Similar strategy is also widely employed 
in cell regulations, especially those involved in cell growth and proliferation, to ensure a 
balanced homeostasis and cell physiology. Feedback inhibition is particularly needed for 
the control of the function of a gene such as p53 whose activity, if not feedback inhibited, 
could lead to an irreversible consequence to the cell such as permanent cell cycle arrest or 
cell death. At low, non-lethal levels of DNA damage, cell cycle progression is delayed by 
the activation of p53 and then p21 to give cells time to repair the DNA and then resumed 
when the repair is completed. The resumption of cell cycle progression is achieved 
through the p53-MDM2 feedback loop in which p53 activates the transcription of its 
primary inhibitor (Barak et al., 1993b; Otto and Deppert, 1993; Wu et al., 1993b). ARF 
gene expression exhibits a strong inverse correlation with the functional status of p53 in 
both human (Robertson and Jones, 1998; Stott et al., 1998) and mouse cells (de Stanchina 
et al., 1998; Zindy et al., 1998), suggesting a possible feedback repression of ARF 
expression by p53. The significance of evolving this second feedback inhibition loop is 
that the first p53-MDM2 negative feedback loop would not be effective to inhibit p53 to 
resume the cell cycle if ARF expression is not repressed: the continuously synthesized 
ARF would bind to and prevent MDM2 from degrading p53. The results presented in this 
chapter provide a molecular basis supporting this feedback regulation.  
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CHAPTER 3 
 
ARF LOCUS IS REPRESSED DIFFERENTLY IN HUMAN AND MICE 
 
60 
Summary 
 
While we already know that mouse Arf is repressed by PcG and HDAC in a p53-
dependent manner, the regulation of human ARF remains elusive. Reports from several 
labs have excluded the role of PcG members, such as Bmi1 and Ezh2, from the 
repression of human ARF, and H3K27 trimethylation markers are not found on hARF 
locus, indicating a totally different mechanism to regulate human ARF, unlike that of 
mouse ARF and p16.  In this chapter I further exclude PcG members CBX7 and MEL18 
from the regulation of human ARF expression. And it is also found that HDAC inhibitor 
TSA and NAM are not able to de-repress human ARF in WI38 cells, although 
inactivation of p53 or Rb pathway can still de-repress ARF expression in human. On the 
other hand, I found that human ARF can be de-repressed by treatment of DNA 
methylation inhibitors 5-aza-2-dexocycytidine or zebularine in a p53- and Rb- 
independent manner. Knocking down DNA methyltransferase 1 and 3a (DNMT1 and 
DNMT3a) by shRNA can slightly increase human ARF expression.  
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Background 
 
Human ARF is regulated very differently from its mouse homolog. The distinct 
regulations reported by multiple groups includes: 1) human ARF can not be repressed by 
Bmi1, Ezh2 or CBX8, and the repressive marker – trimethylated H3K27 – applied by 
PcG is hardly found at ARF locus (Bracken et al., 2007a; Kotake et al., 2007b; Dietrich et 
al., 2007); 2) ectopically expressed histone H3K27 demethylase JMJD3 binds to and 
activates the expression of Arf in mouse, but not in human cells (Agger et al., 2009; 
Barradas et al., 2009; Bracken et al., 2007a; Kheradmand Kia et al., 2009; Kotake et al., 
2007b); 3) Oncogenic Ras can not induce ARF in human cells, despite that it can 
dramatically activate mouse Arf (Berkovich et al., 2003; Brookes et al., 2002; Ferbeyre et 
al., 2000; Wei et al., 2001).  
In human, p53 is still the most promising candidate as the repressor of ARF 
expression. The expression of human ARF has a strong inverse correlation with the 
functional status of p53 in various tumor cell lines(Stott et al., 1998), suggesting a 
repressive role of p53 in ARF regulation consistent with that in mouse (de Stanchina et al., 
1998; Stott et al., 1998; Zindy et al., 1998). However, whether p53 is a direct repressor of 
human ARF, or the inverse correlation is just an indirect effect of p53 loss, still remains 
obscure. 
CBX7 is a chromodomain-binding member of PcG family which can recognize 
the trimethylated H3K27 and recruit PRC1 complex to chromatin (Gil and Peters, 2006). 
It was reported to repress the INK4a/Arf locus in a mutual exclusive manner with Bmi1 
(Gil et al., 2004).  Another member of the PcG family, MEL18, is highly homologous 
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with Bmi1 biochemically and functionally (Goebl, 1991; Ishida et al., 1993). Based on 
the possible repressive role or direct binding on ARF indicated by previous data (Gil et al., 
2004; Maertens et al., 2009), these two PcG members are tested as possible histone 
modifiers in the potential p53- or Rb- mediated repression of human ARF expression. 
Human ARF promoter has been found hypermethylated thus inactivated in 
multiple tumors (Esteller, 2002; Esteller et al., 2001b). Although the hypermethylated 
promoter of tumor suppressors is mostly seen in tumor cells, it is still intriguing to test 
whether the deeply repressed ARF expression in normal human lung fibroblast WI38 is a 
result of promoter methylation.  
In this chapter, to search for possible regulators of human ARF expression, I first 
evaluated whether CBX7 and MEL18 play a role in the repression of ARF, and if yes, 
whether this repression is p53- or Rb- dependent. Then I determined the effects of DNA 
methylation or histone deacetylation on ARF regulation by treating cells with HDAC 
inhibitors or DNA demethylation drugs. Following the observed up-regulating effect on 
ARF expression by DNA demethylation drugs, I knocked down the three functional DNA 
methyltransferase DNMT1, DNMT3a and DNMT3b to further identify the role of DNA 
methylation in ARF repression.  
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Experimental Procedures 
 
Cell culture, western analysis and antibodies 
 
Normal human lung fibroblasts WI38 was cultured in MEM supplemented with 
10% FBS, non-essential amino acid, and sodium pyruvate. 293T cells were cultured in 
DMEM supplemented with 10% NCS. Cells were lysed with 0.5% NP-40 buffer. 
Antibodies to MEL18 (ab5267, Abcam), CBX7 (ab21873, Abcam), DNMT1 (ab13537, 
Abcam) were purchased commercially.   
 
Retroviral procedures 
 
Human CBX7, human MEL-18 cDNA were cloned into pBabe-puro retrovirus 
vector. Retroviruses encoding shRNAs silencing human MEL18, CBX7, 
DNMT1,DNMT3A and DNMT3B were constructed by ligating respective targeting 
oligonucleotides (MEL18-1, CGACGCCACCACTATCGTG ; MEL18-2, 
GATGAAACGGCGGCGGGATTTCTAT; CBX7-1, 
GCGCGTGCGGAAGGGTAAAGT; CBX7-2, GGCTCTCGCGCAAGAAGTTCC; 
DNMT1-1, GGAGCTGTTCTTGGTGGATGA; DNMT1-2, 
GCTTCAATTCGCGCACCTACT; DNMT1-3, GCTTTGTATGTTGGCCAAAGC; 
DNMT3A-1, GCCAAGGTCATTGCAGGAATG; DNMT3A-2, 
GCAGAACAAGCCCATGATTGA; DNMT3A-3, GCGTCACACAGAAGCATATCC; 
DNMT3B-1, GGCAGTAGGAAATTAGAATCA; DNMT3B-2, 
GCCCATTTGACTTGGTGATTG; DNMT3B-3, GGATGAACAGGCCCGTGATAG;) 
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into a PMKO-puro vector. Detailed protocols for retroviral and adenoviral infections 
were described in Chapter 2.  
 
Quantitative-RT-PCR 
 
Detailed protocols of RNA extraction, cDNA synthesis and quantitative PCR are 
described in Chapter 2. Specific PCR pairs were as follows: hCBX7, 5’-
AGCGCGTGCGGAAGGGTAAA-3' and 5’-GGAGCTCCGCAGGTCCATGC-3’; 
hMEL-18, 5’-CCGAACCCAGATGGCCGAAACG-3’, 5’-
CCCCGCAGAGGGCACACATGA-3’ ;hDNMT1, 5’-
AGTCCGATGGAGAGGCTAAGCGT-3’ and 5’-CGTTTGGCAGGGCCCTTTGC-3'; 
hDNMT3a, 5’-CGGCCATACGGTGGAGCCATCG-3’ and 5’-
AGCAGAGCTGCTGGTGTCCCCG-3’; hDNMT3b, 5’-
TCTGGAGAAAGCTAGGGTGCGAGC-3’ and 5’-TGCCTGCACGACGCACCTTC-3’; 
hp21, 5’-CTCAGAGGAGGCGCCATGTCAGA-3’ and 5’-
TGGATGCAGCCCGCCATTAGC-3’; hBAX, 5’-TGGTGCTCAAGGCCCTGTGC-3’ 
and 5’-TTGAGGAGTCTCACCCAACCACCC-3’; hGAPDH, 5’-
GAGTCAACGGATTTGGTCGT-3’ and 5’-GACAAGCTTCCCGTTCTCAG-3’; hp16,  
5’-GAAGGTCCCTCAGACATCCCC-3’ and 5’-CCCTGTAGGACCTTCGGTGAC-3’; 
hARF, 5’-CCCTCGTGCTGATGCTACTG-3’ and 5’-
ACCTGGTCTTCTAGGAAGCGG-3’. 
 
Results 
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PcG members CBX7 and MEL18 are not major repressors of human ARF 
 
Based on the previous report of a possible repressive role of CBX7 in human ARF 
transcription (Gil et al., 2004), and the binding of MEL18 on human ARF locus 
(Maertens et al., 2009), I wanted to determine whether the two PcG members repress 
human ARF in cooperation with p53 or Rb.  
 
Therefore, I first knocked down CBX7 or MEL18 expression in WI38/mock, 
WI38/E6, and WI38/E7 by retroviral expression of shRNA. While knocking down 
efficiency achieves 60% - 70% of mRNA loss for both genes (Figure 3.1 A and B), the 
effects on ARF expression is moderate at most. CBX7 deficiency did not up-regulate ARF 
mRNA in mock cells, but increased ARF expression by 50% - 60% in E6 and E7 WI38 
(Figure 3.1 A), indicating CBX7 does not have a significant role in repressing ARF. The 
inconsistency of this data with previous reports might be due to different knocking down 
efficiency, in other words, the remaining CBX7 after shRNA targeting is still enough to 
repress ARF expression. On the other hand, knocking down MEL18 did increase ARF 
expression by 60% in WI38/MOCK, and the up-regulating effects are dropped in E6 and 
disappeared in E7 cells (Figure 3.1 B), showing that MEL18 might repress ARF in a p53 
or Rb dependent manner, but the overall effects are not significant enough to make a 
solid conclusion.  
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I also overexpressed these two PcG members by retrovirally transducing 
WI38/MOCK, WI38/E6 and WI38/E7 cells to further characterize the role of CBX7 and 
MEL18 in ARF expression. ARF expression was hardly effected by overexpression of 
CBX7 or MEL18, despite the high expression of these two PcG members in all three 
human cells tested (Figure 3.1 C and D).  
 
Based on both the knocking down and overexpression results, I found that the 
roles of CBX7 and MEL18 in repressing human ARF are quite ambiguous, therefore it is 
not wise to carry on further experiments on this project.  
 
Figure 3.1 
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Figure 3.1. PcG members CBX7 and MEL18 are not major repressors of human 
ARF.   
 (A) and (B) WI38 MOCK/E6/E7 at passage 34 were infected by retrovirus expressing 
either mock or CBX7-targeting or MEL18-targeting shRNA and selected with 1 uM 
puromycin for 3 days. Cells were collected 6 days after infection and analyzed for mRNA 
level of CBX7, MEL18, and ARF by Q-RT-PCR. Data were expressed relative to the 
corresponding values of mock-infected cells, and means and standard deviations were 
calculated from triplicates of three independent experiments.  
 
(C) and (D) WI38 MOCK/E6/E7 at passage 34 were infected by retrovirus expressing 
either mock or CBX7 or MEL18 and selected with 1 uM puromycin for 3 days. Cells 
were collected 7 days after infection and analyzed for mRNA level of CBX7, MEL18, 
and ARF by Q-RT-PCR, for protein level by western blot. Data were expressed relative 
to the corresponding values of mock-infected cells, and means and standard deviations 
were calculated from triplicates of three independent experiments.  
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Human ARF expression can not be activated by HDAC inhibitors 
 
That mouse Arf expression is repressed by HDAC leads us to evaluate whether 
this also applies to the human system. By utilizing luciferase reporter assay to measure 
promoter activity, Matheu et al reports that human ARF promoter can also be activated by 
HDAC inhibitors TSA and NaB in HEK-293T cells(Matheu et al., 2005). However in 
WI38 cells, I did not detect significant increase of ARF expression with either TSA 
(inhibitor of HDAC Class I/II) treatment or NAM (inhibitor of HDAC SIRT family) 
treatment (Figure 3.2). Neither low nor high concentration of TSA (0.1uM and 5uM) 
could activate human ARF expression. The inconsistency between our data and the 
previous report might be due to different cell system (293T vs WI38), or different 
analyzing methods (luciferase assay vs RT-PCR), etc.  Comparing to the dramatic 
increase of ARF expression by TSA treatment in MEFs, the inability of HDACi to de-
repress human ARF further supports the difference in regulating human and mouse ARF 
expression. 
 
The dominance of DNA hypermethylation over histone deacetylation in gene 
repression (Cameron et al., 1999) suggests another explanation for the insensitivity of 
human ARF locus to HDACi. To evaluate this possibility, future study is needed to 
decide whether the ARF locus is hypermethylated in the tested cell lines tested, and 
whether demethylation of promoter can facilitate HDACi to de-repress ARF locus.  
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Figure 3.2 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Human ARF expression can not be activated by HDAC inhibitors  
WI38 cells at passage 35 were treated by DMSO, TSA or NAM for 24hs. Cell pellets 
were then collected and analyzed for mRNA level of ARF by Q-RT-PCR. Data were 
expressed relative to the corresponding values of DMSO-treated cells, and means were 
calculated from triplicates of a representative experiment.  
 
Human ARF expression is elevated when p53 or Rb pathway is inactivated  
 
The inverse correlation of ARF expression with p53 function status in multiple 
human tumor cell lines (Stott et al., 1998) suggests that p53 might also be a direct 
repressor of ARF in human. In WI38 cells, ARF expression is elevated to about 2.4 folds 
and 6.8 folds when p53 or Rb pathway is inactivated by E6 or E7, respectively (Figure 
3.3A). The more dramatic ARF mRNA elevation caused by Rb inactivation raised the 
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question of whether Rb, instead of p53, plays a more important role in repression of 
human ARF.  
 
While adenovirally reintroducing p53 back to WI38/E6 can restore the repression 
of ARF (Figure 3.3B), activation of endogenous p53 with Nutlin-3 in either WI38/MOCK 
or WI38/E7 can only slightly enhance the transcriptional repression of ARF (Figure 3.3C). 
Here p21 expression is a positive control showing p53 activation. The different 
information yielded by those two pieces of data might suggest a dose-dependent effect, in 
which adenoviral overexpression introduces much more p53 than the amount released 
from MDM2-mediated inhibition. The very low expression level of ARF in WI38 might 
also be a factor that limits further repression by p53, however this is not applicable to 
WI38/E7 cells in which ARF expression is already greatly increased. Whether the data in 
WI38/E7 cells suggests a minor role of p53 in repressing human ARF, or a requirement of 
Rb function in p53-mediated repression of ARF is very intriguing.  
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Figure 3.3 
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Figure 3.3. Human ARF expression is elevated when p53 or Rb pathway is 
inactivated  
(A) WI38 MOCK/E6/E7 cells at passage p34 were analyzed for mRNA level of ARF and 
p16 by Q-RT-PCR. Data were expressed relative to the corresponding values of MOCK 
cells, and means and standard deviations were calculated from triplicates of three 
independent experiments.  
 
(B) WI38/E6 cells were infected by adenovirus expressing either GFP or human p53. 
Cells were collected 2 and 3 days after infection and the expression levels of p21 and 
ARF were measured by Q-RT-PCR. Data were expressed relative to the corresponding 
values of GFP-infected cells, and means and standard deviations were calculated from 
triplicates of two independent experiments. 
 
(C) WI38/MOCK and WI38/E7 cells were treated with either DMSO or 10uM Nutlin-3 
for 24hs and the mRNA levels of p21 and ARF were measured by Q-RT-PCR. Data were 
expressed relative to the corresponding values of DMSO-treated cells, and means and 
standard deviations were calculated from triplicates of two independent experiments. 
 
DNA demethylation drug can activate human ARF expression in WI38 cells 
 
Promoter hypermethylation of ARF has been found in numerous tumors (Esteller 
et al., 2001b) and is an important alternative mechanism to inactivate the ARF-p53 
pathway in addition to ARF gene deletion. 5-Aza-2-deoxycytidine and zebularine are 
potent DNA demethylation drugs, and ARF transcription in WI38/MOCK, WI38/E6 and 
WI38/E7 cells were increased to 2 - 4 folds after 2 days of drug treatment (Figure 3.4). 
That ARF de-repression by DNA demethylation drugs was not affected by E6 or E7 loss 
suggests independent pathways might be used by p53/Rb and DNA methylation to 
repress ARF expression in human.  
 
Since promoter hypermethylation occurs more often in tumor cell lines instead of 
normal tissue/cell, it is not clear whether the de-repression of ARF by DNA 
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demethylation drug in WI38/MOCK – which is normal human fibroblast - is due to direct 
effect of promoter demethylation, or indirect effect of demethylation of other gene locus. 
To have a better understanding of this, I am trying to evaluate the methylation status of 
ARF promoter by methylation-specific PCR and bisulfate sequencing. Switching this 
DNA demethylation drug treatment to a cell line known to hypermethylated at ARF locus, 
such as U2OS and HCT116, is also a next step in this project.  
 
Figure 3.4 
 
 
 
 
 
 
 
 
Figure 3.4. DNA demethylation drug can activate human ARF expression in WI38 
cells  
WI38 MOCK/E6/E7 cells at passage p34 were treated by DMSO, 1uM 5-Aza or 100uM 
zebularine for 48 hours and then analyzed for mRNA level of ARF by Q-RT-PCR. Data 
were expressed relative to the corresponding values of DMSO cells, and means and 
standard deviations were calculated from triplicates of three independent experiments.  
 
Knocking down DNMT1 or DNMT3a can slightly increase human ARF expression 
in WI38 cells 
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DNA methylation on CpG islands is catalyzed by DNMT1, DNMT3a and 
DNMT3b. Of these three functional enzymes, DNMT1 is responsible for the maintenance 
of methylation after DNA replication, while DNMT3a and DNMT3b are de novo 
methyltransferases. Following the study in Figure 3.4 which suggests DNA methylation 
might be have a role to repress human ARF in WI38, I tried to knock down DNMT1, 
DNMT3a and DNMT3b, respectively, in WI38 by shRNA. Partly due to the different 
expression level in which DNMT1 > DNMT3a > DNMT3b, DNMT1 achieves 80% to 
90% knocking down efficiency, while DNMT3A got 50% ~60% mRNA loss, and the 
barely-expressed DNMT3b was not knocked down at all (Figure 3.5).  
 
Knocking down DNMT1 and DNMT3a can increase ARF expression to 1.7 and 
1.5 fold respectively (Figure 3.5). Although the effects are not dramatic, several factors 
need to be considered to interpret this result: 1) WI38, as the normal fibroblast, might not 
be the best system to study DNA methylation, and we might be able to see more 
significant role of DNMTs in repressing ARF in cell lines like HCT116 or U2OS; 2) the 
deficient function of one DNMT might get compensated by the others (Rhee et al., 2002), 
therefore simultaneous knocking down of two or three DNMT might be required to de-
repress gene expression.  
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Figure 3.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Knocking down DNMT1 or DNMT3a can slightly increase human ARF 
expression in WI38 cells 
WI38 MOCK/E6/E7 cells at passage p33 were transduced by retrovirus expressing either 
shRNA targeting DNMT1, DNMT3a, or DNMT3b. Cells were selected by 1uM 
puromycin for 3 days and collected 6 days after infection. The knocking down efficiency 
and ARF expression were analyzed by Q-RT-PCR. Data were expressed relative to the 
corresponding values of mock-infected cells, and means and standard deviations were 
calculated from triplicates of a representative experiment.  
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Discussion 
 
In this Chapter, I first excluded PcG members CBX7 and MEL18 from the 
regulation of human ARF expression through both genes knock down and overexpression. 
Although deeply repressed as human p16 locus and mouse p16/Arf locus, human ARF 
promoter is lack of the repressive marker of H3k27me3 applied by PcG {Bracken, 2007 
#75}. Therefore, there raised an intriguing question: is there another histone repressive 
marker on human ARF locus and which? Methylation on histone H3K9 or H4K20 are 
good candidates and the methyltransferases responsible for them are interesting research 
targets.  
 
The data presented here also showed de-repression of human ARF when p53 or 
pRb is inactivated. Although p53 is supposed to be a more promising candidate for 
directly repressing human ARF expression because of previous reports, Rb seems to have 
more significant role in repressing human ARF based on the more dramatic de-repression 
effects seen in E7 cells. To answer this question, an essential experiment is to determine 
whether p53 or Rb family members directly bind to human ARF locus. 
 
Very different from the case in MEFs, HDAC inhibitors can not de-
repress/activate ARF expression in human. Does this exclude HDAC from the repression 
of human ARF? Not necessarily so. Histone deacetylation has been linked with DNA 
hypermethylation and methylation of histone H3K9 in the silencing of gene expression. 
Methylated DNA and methy-CpG-binding protein MeCP2 can recruit histone deacetylase 
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(HDAC) to repress transcription (Eden et al., 1998; Jones et al., 1998; Nan et al., 1998). 
Moreover, DNA methylation is dominant over deacetylation for the stable maintenance 
of the silent loci (Cameron et al., 1999), which means HDAC inhibitor might not be able 
to de-repress gene expression if the locus is hypermethylated. Therefore a combination of 
HDACi and DNA demethylation treatment might uncover the possible repressive role of 
HDAC in human ARF regulation.  
 
I found that the human ARF locus can be de-repressed by DNA demethylation 
drugs, and knocking down DNMT has some slight effect to increase ARF expression. 
However before we go any further, one essential question is: is the human ARF promoter 
methylated in the normal human cell WI38? Although people in this field usually think 
the hypermethylation of tumor suppressors only occurs in tumors, this is not always the 
case. There are still tumor cell lines without hypermethylated ARF promoter and normal 
cells with DNA methylation detected on the ARF locus. If there is no DNA methylation 
on human ARF, the increase of ARF expression upon demethylation treatment might be 
due to some indirect effects. Adding a tumor cell line with hypermethylated ARF 
promoter, such as U2OS or HCT116, to the study would also be very helpful. On the 
other hand, the DNA demethylation drug 5-aza-2-dexocycytidine and zebularine can both 
de-repress ARF in a p53- and Rb- independent manner, indicating that the repression of 
human ARF by DNA methylation (if any) and p53/Rb is functionally independent.  
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CHAPTER 4 
 
HISTONE MODIFIERS ARE INVOVLED IN THE ONCOGENIC INDUCTION 
OF ARF EXPRESSION 
 79 
 
Summary 
 
ARF expression can be potently activated by oncogenic/proliferative stress in both 
human and mouse, while the direct transcription factors responsible for this process 
remain obscure. In this Chapter I evaluated the dynamic binding of E2F transcription 
factors and histone/DNA modifiers on ARF during oncogenic/proliferative stress. In the 
mouse embryonic fibroblasts, I found decreased Ring1B binding to the Arf locus 
associated with the activation of mouse Arf by H-RasG12V. By using inducible E2F1 
stable cells – WI38/ER-E2F1, I observed more than 20 fold increase of ARF expression 
in the proliferative stress cause by E2F1, which was interestingly accompanied by 
increased E2F1 binding, decreased E2F3 binding and decreased trimethylated H3K9 on 
ARF locus.  
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Background 
 
Under oncogenic or hyperproliferative stress, the expression of p16 and ARF is 
activated to induce premature senescence or apoptosis, which acts as an effective defense 
mechanism against the transformation effect of oncogenic signals(de Stanchina et al., 
1998; Sherr, 2001; Zindy et al., 1998). The mechanism underlying this event is still 
poorly understood after more than one decade.  
 
There are reports indicating that Ras signals through the RAF-MEK-ERK kinase 
cascade to enhance the binding of transcription factor Dmp1 to mouse Arf thus inducing 
Arf expression, and Ras can not activate Arf in Dmp1 -/- MEFs (Inoue et al., 1999; 
Sreeramaneni et al., 2005). However, oncogenic Ras can not activate ARF in human cells 
(Berkovich et al., 2003; Brookes et al., 2002; Ferbeyre et al., 2000; Wei et al., 2001). 
E2F1 is also a relatively better understood hyperproliferative activator of ARF expression 
(DeGregori et al., 1997; Phillips et al., 1999). A dramatic recruitment of E2F1, 2 and 3a 
to the mouse Arf locus was observed under oncogenic stress induced by overexpressing 
E2F1 or E1A (Aslanian et al., 2004; Iaquinta et al., 2005), suggesting that the E2F family 
might be direct transcriptional activators of Arf, although Arf is not a classic E2F-
responsive genes structurally or functionally (Berkovich et al., 2003; Iaquinta et al., 2005; 
Parisi et al., 2002).   
 
Previous reports have linked the dynamic changes of H3K27me3, H3K4me3 and 
their methylase/demethylase on the p16 locus with oncogenic induction of p16 by Ras. 
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Overexpression of H-RasG12V can dissociate Bmi1 from the INK4a locus, decrease 
trimethylation of H3K27 and increase trimethylation of H3K4, while the binding of  the 
H3K4 methyltransferase MLL1 to INK4a is unchanged (Kotake et al., 2009). The 
expression of the H3K27 demethylase JMJD3 is induced upon Ras-mediated oncogenic 
stress, and JMJD3 is recruited to the INK4a locus and contributes to the transcriptional 
activation of INK4a in human cells (Agger et al., 2009). 
 
Here I determined whether oncogenic stresses induce the expression of mouse Arf 
by removing PcG from the Arf locus. Since human ARF is not repressed by PcG and no 
H3K27me3 has been detected on the human ARF locus (Bracken et al., 2007a; Kotake et 
al., 2007b), I evaluated the binding of E2F1, E2F3, Dnmt1 to the human ARF locus 
instead of PcG under E2F1-induced hyperproliferative stress. In the mean time, several 
important histone modifications other than H3K27me3, such as H3K4me3, H3K9me2, 
H3K9me3, were also tested on the ARF locus.  
 
Experimental Procedures 
 
Cell culture, western analysis and antibodies 
 
The WI38 cells stably expressing ER-E2F1 were kindly provided by Dr. Ned 
Sharpless. MEFs were cultured in DMEM supplemented with 10% FBS. Normal human 
lung fibroblasts WI38 was cultured in MEM supplemented with 10% FBS, non-essential 
amino acid, and sodium pyruvate. 293T cells were cultured in DMEM supplemented with 
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10% FBS. MEFs were lysed with RIPA buffer. Antibodies to E2F3 (sc-193X, Santa 
Cruz), H3K4me3 (ab8580, Abcam), H3K9me3 (ab8898, Abcam), H3K9me2 (ab1220, 
Abcam),E2F3 (sc-878X, Santa Cruz) were purchased commercially.   
 
Retroviral and adenoviral procedures 
 
The pBabe retroviral vectors expressing E2F1, K-Ras, H-Ras, and ER-Myc, and 
WI38/ER-E2F1 cells were kindly provided by Dr. Ned Sharpless. Detailed procedures of 
retroviral infection were described in Chapter 2.  
 
ChIP assay 
 
Detailed protocols for ChIP analysis were described in Chapter 2. Following 
primers were used for Q-PCR of human Arf locus: hARF-1, 5’-
TGCAGGCCTCACTTTCCTC-3’ and 5’-CCAGAGGATTCGGGACTAGG-3’; hARF-2, 
5’-GTCCGAGTTCCTGGACGAG-3’ and 5’-CAGCTGGGAGACAGGAAAAG-3’; 
hARF-3, 5’-GCGACTCCACCTACCTAGTCC-3’ and 5’-
CTCTATCCGCCAATCAGGAG-3’; hARF-4, 5’-CGAGCAGCACCAGAATCC-3’ and 
5’-ACTTTCCCGCCCTGTGTG-3’. 
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Results 
 
Activation of mouse Arf by oncogenic stress is associated with decreased Ring1B 
binding on Arf  
 
Confirming the activation of mouse Arf by oncogenic stress, I transduced WT 
MEFs with retrovirus overexpressing H-Ras, K-Ras, myc and E2F1. Expression of Arf 
was greatly increased by all three oncogenic/proliferative stresses and the most dramatic 
effect was seen with H-Ras (Figure 4.1A). In order to evaluate the induction of ARF 
expression by oncogenic insult in a more systemic manner, a time course experiment was 
conducted by utilizing WT MEFs that can stably express ER-myc.  Induction of ER-myc 
by 4-OH-tamoxifen can activate ARF transcription to more than 2 folds within 17 hours, 
and the activation peaks at ~ 23 folds within 2 days (Figure 4.1B).  
 
A 50%-60% reduction of Ring1B binding on mouse Arf locus was detected in 
accordance with the activation of Arf by H-Ras (Figure 4.1C), whereas the bindings of 
p53 and HDAC1 to Arf were not affected by H-Ras overexpression (data not shown). 
This data suggests that, of the multistep p53-HDAC1-PcG recruitment to mouse Arf locus, 
oncogenic Ras might targets only the PcG to induce Arf expression. 
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Figure 4.1 
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Figure 4.1.  Activation of mouse Arf by oncogenic stress is associated with decreased 
Ring1B binding on Arf 
(A) WT MEFs at passage 3 were infected by retrovirus expressing H-Ras, K-Ras, myc or 
E2F1 and selected by 2ug/ml puromycin for 2 days. Cells were collected 4 days post 
infection and analyzed for Arf expression by western analysis.  
 
(B) WT MEFs at passage 3 were infected by retrovirus expressing ER-myc and myc was 
induced by 1ug/ml 4-OH-tamoxifen for indicated time lengths. Cells were collected at 
indicated time points and the mRNA level of Arf is determined by Q-RT-PCR. Data were 
expressed relative to the value of un-induced MEFs. Means were calculated from 
triplicate of one representative experiment.   
 
(C) MEFs transduced by H-Ras in (A) were collected 4 days post infection and analyzed 
for binding of Ring1B on Arf locus. Data were expressed relative to the value of vector 
infected MEFs. Means and standard deviations were calculated from triplicate of three 
independent experiments. 
 
 
Overexpression of E2F1 in WI38 can activate ARF expression and causes 
enrichment of E2F1 binding and decreased E2F3 binding on ARF locus 
 
Although oncogenic Ras can not affect human ARF expression, overexpression of 
E2F1 in human fibroblast WI38 increases ARF expression by up to 5 fold within only 7 
hours, and the up-regulation reaches 20 fold in one day (Figure 4.2A). p16 expression is 
also greatly activated by E2F1 overexpression, but in a less extent than that of ARF. Two 
indicators for downstream effects of the ARF-p53 pathway, p21 and BAX, are differently 
influenced by the E2F1 induction: p21, but not BAX, is activated by overexpression of 
E2F1 (Figure 4.2A). The activation of p21 instead of BAX indicates that overexpression 
of E2F1 in WI38 preferentially leads to cell cycle arrest, not apoptosis.   
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Based on the regulatory role of E2F1 and E2F3 in ARF expression, and the de-
repression effect of DNA demethylation on ARF (described in Chapter 3),  I first tested 
the binding of E2F1, E2F3 and DNMT1 on ARF locus in WI38. E2F1 and E2F3 bind to 
human ARF in WI38 with a similar manner (Figure 4.2B), while little binding of DNMT1 
was detected on ARF locus. Interestingly, the binding of E2F1 to ARF locus is increased 
to 4~5 folds when E2F1 is induced, whereas E2F3 is dissociated from ARF locus by 60% 
to 70% (Figure 4.3C). This is consistent with previously reported roles of E2F1 (activator) 
and E2F3 (b) (repressor) in mouse Arf regulation (Aslanian et al., 2004). However due to 
the high expression level of E2F1 upon induction, the increased binding of E2F1 and 
decreased binding of E2F3 might partly result from the dose advantage of E2F1 over 
E2F3, since the two might compete for E2F binding sites on ARF. Therefore the dynamic 
binding of E2F1 and E2F3 on ARF upon oncogenic insult needs to be further justified in 
another oncogenic/proliferative stress other than E2F1, such as myc.   
Figure 4.2 
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Figure 4.2.  Overexpression of E2F1 can activate hARF expression and causes 
enrichment of E2F1 binding and decreased E2F3 binding on ARF locus 
(A) Human fetal lung fibroblast WI38 that are stable expresses ER-E2F1 is treated with 
4-OH-tamoxifen for the indicated time length. Cell pellets were collected at indicated 
time points and the mRNA level of ARF, p16, p21 and BAX are determined by Q-RT-
PCR. Data were expressed relative to the value of un-induced WI38. Means were 
calculated from triplicate of two independent experiments.   
 
(B) The binding of E2F1, E2F3 and DNMT1 to ARF locus were tested in WI38 cells by 
ChIP analysis. DNA amounts in the immnoprecipitated complexes were expressed 
relative to input DNA. Means and standard deviations were calculated from triplicate of 
three independent experiments.   
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(C) WI38/ER-E2F1 is induced by 4-OH-tamoxifen for 48 hours and the cells were 
collected for analyzing the binding of E2F1 and E2F3 on ARF locus. Data were 
expressed relative to the value of un-induced WI38. Means and standard deviations were 
calculated from triplicate of three independent experiments. 
 
Activation of human ARF by E2F1 overexpression is accompanied by changes of 
histone methylation on ARF locus 
 
The amounts of histone H3K4me3, H3K9me2 and H3K9me3 on ARF locus were 
determined by ChIP analysis in WI38. H3K27me3 was not included here because 
previous research (Bracken et al., 2007a) indicates this modification does not exist on 
human ARF locus. As shown in Figure 4.3A, although both H3K9me2 and H3K9me3 
exist on human ARF promoter, there is a much higher level of H3K4me3 on the same 
locus. Since ARF is expressed at a very low level in WI38, the detection of corresponding 
repressive markers H3K9me2 and H3K9me3 is not very surprising, but we did not expect 
to see such a high level of gene activation marker H3K4me3.  The large amount of 
H3K4me3 has also been detected on the deeply repressed mouse Arf/p16 locus (data not 
shown), indicating an overall high level of this histone markers that not necessarily 
represents the transcription status of gene loci.  
 
When WI38/ER-E2F1 cells were induced by 4-OH-tamoxifen, the H3K9me3 on 
ARF is decreased by 50% to 60% due to E2F1 overexpression, however only slight 
decrease of H3K9me2 was observed, and there was hardly any increase of H3K4me3 on 
ARF (Figure 4.3B). Considering the highly up-regulated ARF expression upon E2F1 
overexpression (Figure 4.2A) and the large amount of this modification on repressed ARF 
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locus, H3K4me3 might be a poor indicator of transcription status of this locus. The data 
shown here provides useful information for identifying histone modifiers on human ARF 
locus. And because of the close crosstalk between DNA methylation and H3K9 
methylation, it is intriguing to determine how these two modifications interplay in the 
oncogenic/proliferative induction of human ARF expression.  
Figure 4.3 
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Figure 4.3.  Activation of human ARF by E2F1 overexpression is accompanied by 
changes of histone methylation on ARF locus 
(A) The amount of H3K9me2, H3K9me3 and H3K4me3 on ARF locus were determined 
in WI38 cells by ChIP analysis. DNA amounts in the immnoprecipitated complexes were 
expressed relative to input DNA. Means and standard deviations were calculated from 
triplicate of two independent experiments.   
 
(B) WI38/ER-E2F1 is induced by 4-OH-tamoxifen for 48 hours and the cells were 
collected for analyzing the amount of H3K9me2, H3K9me3 and H3K4me3 on ARF locus. 
Data were expressed relative to the value of un-induced WI38. Means and standard 
deviations were calculated from triplicate of two independent experiments. 
 
 
Discussion 
 
In this part of my study, I found the changed binding of E2F family and decreased 
H3K9me3 level on human ARF locus during the hyperproliferative stress, by utilizing the 
inducible cell system of WI38/ER-E2F1. The observation of E2F1 enrichment and E2F3 
dissociation on ARF is interesting, but the mechanistic significance of this data will be 
greatly enhanced if the dose effects of E2F1 can be excluded in another oncogenic stress 
system other than E2F1 overexpression, such as myc. Since there is no specific E2F3b 
antibody (because all domains of E2F3b is included in E2F3a, refer to Figure 1.7), anti-
E2F3a can be included in future E2F3 ChIP analysis to differentiate the binding of E2F3a 
and E2F3b on ARF locus.   
 
No dnmt1 binding was found on ARF locus in WI38, despite the de-repression of 
ARF by 5-Aza and zebularine. Similarly to Chapter 3, using a tumor cell line with 
hypermethylated ARF promoter will significantly enhance our understanding of the 
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regulation of human ARF by DNA methylation.  If DNMT binds to ARF and ARF 
expression can be activated by oncogenic stress in this tumor cell line, we can further 
characterize the oncogenic induced ARF activation by checking whether DNA 
hypermethylation are overcome by oncogenic stress, and whether DNMT is removed 
from ARF locus during the activation process.  
 
H3K9me2/me3 and methylation of DNA are usually concentrated at 
transcriptionally silenced genes and constitutive heterochromatin (Fahrner et al., 2002; 
Lehnertz et al., 2003; Tariq et al., 2003). There are at least 5 H3K9 methyltransferase in 
mammals: Suv39h1 (tri-), Suv39h2 (tri-), G9A (di-), Eset/SETDB1 (di- and tri-), and 
EuHMTase. G9A and SETDB1 are mainly for mediating the silencing of euchromatic 
genes, while Suv39H1  and Suv39H2  are usually responsible to modify H3K9 at 
constitutive heterochromatin (Stancheva, 2005). H3K9me2 is a mark of facultative 
(reversible) heterochromatin while H3K9me3 is of constitutive heterochromatin 
(irreversible) (Sarma and Reinberg, 2005). Although there is study suggesting DNMT1-
G9a-H3K9me2 axis in the repression of p16 expression (Yamakoshi et al., 2009), up to 
now there is no report indicating human ARF is a heterochromatic locus. Why the tri- and 
di- methylation of H3K9 exist on human ARF locus at a similar level and why only 
H3K9me3 level is reduced upon E2F1-mediated ARF activation, is an important question 
to answer. Characterizing the possible role of G9A or Suv39h1/2 in repressing human 
ARF will further clarify the mechanisms.  
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Our lab has reported the activating function of histone H3K4me3 
methyltransferase MLL1 in p16 expression (Kotake et al., 2009). As shown in Figure 
4.3A, the level of H3K4me3 on human ARF locus is high in WI38 and unchanged during 
E2F1-mediated oncogenic stress. Is MLL involved in the regulation of human ARF? 
Does it bind to human ARF locus and will the binding be changed during oncogenic 
stress? Those will all be intriguing questions to answer.  
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CHAPTER 5 
 
CONCLUSIONS AND PERSPECTIVES
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p53-mediated recruitment of PcG and HDAC to mouse Arf locus 
 
Over the past four years, my thesis study has been focused on the transcriptional 
regulation of ARF tumor suppressor, and the regulation of mouse Arf expression 
constitutes the major part of my research. The data in this part demonstrated that p53 
binds to and represses mouse Arf expression by recruiting PcG and HDAC to Arf locus. 
Figure 5.1 shows the function model based on the results presented here: p53 binds 
specifically to the Arf locus and then recruits HDAC to deacetylate the Arf locus; 
deacetylation of the Arf locus then facilitates the recruitment of PRC to the Arf locus, 
leading to H3K27 trimethylation and silencing of Arf expression.  
 
 
 
 
 
 
 
 
 
Figure 5.1.  A schematic model illustrating p53-mediated Arf repression 
by HDAC and PcG. 
 
The p53-Arf negative feedback regulatory loop parallels with the RB-p16 
feedback regulatory loop in which RB proteins down-regulate their activator, p16 CDK 
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inhibitor (Kotake et al., 2007a). The similarity can be seen at two levels: functionally, 
both feedback loops were evolved to prevent a permanent cell cycle arrest; and 
mechanistically, both operate via a transcriptional repression. There is, however, a critical 
difference between these two feedback loops: while polycomb has been shown to bind to 
and repress p16 transcription in both mouse and human cells, it only binds to and 
represses the transcription of Arf in mouse, but not in human cells (Bracken et al., 2007b; 
Kheradmand Kia et al., 2009; Kotake et al., 2007a). Supporting a distinct role of 
polycomb in the repression of Arf transcription between mouse and human cells, 
ectopically expressed histone H3K27 demethylase JMJD3 binds to and activates the 
expression of Arf in mouse, but not in human cells (Agger et al., 2009; Barradas et al., 
2009). Our study sheds new light into this issue by showing that histone deacetylation 
plays a very critical role in the repression of mouse—but not human—ARF transcription. 
It will be interesting to determine both biochemically and genetically why ARF 
transcription is repressed by p53 in both human and mouse cells, but only mouse Arf is 
repressed by histone deacetylation.   
 
My study also adds to the understanding of p53-mediated transcriptional 
repression, an area that is much less understood than p53-mediated transcriptional 
activation even though it was estimated that as many as 15% of genes containing a p53 
response element can be repressed by p53 [see recent review by (Menendez et al., 2009; 
Riley et al., 2008)]. p53 has been reported to directly bind with mSin3A, a transcriptional 
co-repressor and a member of class I HDAC complexes and recruit HDACs to a specific 
promoter such as Map4 or Nanog (Lin et al., 2005; Murphy et al., 1999). Our study 
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provides two separate lines of evidence supporting a role of histone deacetylation in p53-
mediated repression of Arf. First, we showed that treatment of MEFs with a low 
concentration of TSA drastically increased Arf mRNA (>15-fold) and this effect is seen 
as early as 6 hours (Figure. 2.3). Second, we demonstrate that HDAC1 directly binds to 
and deacetylates Arf in a p53 dependent manner. We further identify a new mechanism—
recruiting PRC—for p53-mediated transcriptional repression. To the best of our 
knowledge, this represents the first evidence that p53-mediated repression involves 
polycomb repressive complex which contains histone modifying activities known to 
function in silencing gene expression. Conversely, identification of a sequence-specific 
binding factor—p53—in the recruitment of PRC to a specific locus also help to better 
understand how PcG is recruited to their targets, a puzzling issue associated with the 
repression of many PRC-regulated genes in mammalian cells. 
 
Is formation of 5hmC by TET1 a new mechanism to repress ARF promoter? 
 
Although DNA methyltransferases have been well characterized for more than a 
decade, DNA demethylase has not been found yet. Recently people discovered the “6th” 
base of nucleoside -- 5-hydroxymethylcytidine (5hmC), in addition to the four canonical 
DNA nucleosides -- dA, dC, dG, dT-- and the“5th” base -- 5mC. The enzyme TET1 has 
been found responsible for the conversion of 5mC to 5hmC in an Fe (II) and α-KG 
dependent manner (Ito et al., 2010; Kriaucionis and Heintz, 2009; Munzel et al., 2010; 
Tahiliani et al., 2009). Since switching methylation to hydroxymethylation is an essential 
intermediate step for demethylation of protein, people in this field are speculating 
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whether this is also the case for DNA thus DNA demethylation may be a TET1-mediated 
process. Whether the 5hmC is an intermediate for oxidative DNA demethylation process, 
or a stable end-product acting as a new epigenetic regulator of gene expression is of great 
interest.  
To link 5hmC to regulation of ARF expression, the first step is identifying 
whether there is 5hmC on ARF locus. There are already functional assays available to test 
the existence and relative abundance of 5hmC, and a scheme of the theoretic approach 
from New England Biolabs is shown in Figure 5.2.  If such DNA modifications are found 
on ARF locus, we can further determine whether TET1 plays a role in regulating ARF 
expression. And we also need to reconsider the previous data of DNA methylation on 
ARF promoter, because they might represent a combination effect of 5hmC and 5mC.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Analysis of 5hmC on gene locus. From 
http://www.neb.com/nebecomm/tech_reference/Epigenetics/EpiMark.asp. 
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Summary 
 
 To sum up, my research into the regulation of ARF tumor suppressor has linked 
epigenetic modifiers to the p53 mediated repression of ARF and oncogenic induction of 
ARF expression. Despite the ample new reports in this field every year, we might have 
only touched the surface of the complicated regulation network of ARF transcription. 
Systematic approaches for identifying histone or DNA modifications/modifiers on gene 
locus will give us new hints or directions for better understanding the dynamic 
transcriptional regulation network. The findings on non-coding RNA mediated regulation 
of p15/ p16 expression also points out novel perspectives of potential new regulators 
other than proteins in ARF regulation. These mechanistic studies may give us new 
insights to resolve the puzzles in the regulation of ARF expression, such as differential 
regulation of ARF in mouse and human, coordinate vs independent regulation of the 
whole p15/ARF/p16 locus.  
 
  
 
 99 
 
 
REFERENCES 
 
 100 
 
Adams, M.R., Sears, R., Nuckolls, F., Leone, G., and Nevins, J.R. (2000). Complex 
transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell 
Biol 20, 3633-3639. 
Agger, K., Cloos, P.A., Rudkjaer, L., Williams, K., Andersen, G., Christensen, J., and 
Helin, K. (2009). The H3K27me3 demethylase JMJD3 contributes to the activation of the 
INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev 
23, 1171-1176. 
Aslanian, A., Iaquinta, P.J., Verona, R., and Lees, J.A. (2004). Repression of the Arf 
tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev 18, 1413-
1422. 
Bannister, A.J., Zegerman, P., Partridge, J.F., Miska, E.A., Thomas, J.O., Allshire, R.C., 
and Kouzarides, T. (2001). Selective recognition of methylated lysine 9 on histone H3 by 
the HP1 chromo domain. Nature 410, 120-124. 
Barak, Y., Juven, T., Haffner, R., and Oren, M. (1993a). mdm2 expression is induced by 
wild type p53 activity. Embo J 12, 461-468. 
Barak, Y., Juven, T., Haffner, R., and Oren, M. (1993b). Mdm-2 expression is induced by 
wild-type p53 activity. EMBO J 12, 461-468. 
Barradas, M., Anderton, E., Acosta, J.C., Li, S., Banito, A., Rodriguez-Niedenfuhr, M., 
Maertens, G., Banck, M., Zhou, M.M., Walsh, M.J., et al. (2009). Histone demethylase 
JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev 
23, 1177-1182. 
Berkovich, E., Lamed, Y., and Ginsberg, D. (2003). E2F and Ras synergize in 
transcriptionally activating p14ARF expression. Cell Cycle 2, 127-133. 
Bernard, D., Martinez-Leal, J.F., Rizzo, S., Martinez, D., Hudson, D., Visakorpi, T., 
Peters, G., Carnero, A., Beach, D., and Gil, J. (2005). CBX7 controls the growth of 
normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene 24, 
5543-5551. 
Bernstein, B.E., Kamal, M., Lindblad-Toh, K., Bekiranov, S., Bailey, D.K., Huebert, 
D.J., McMahon, S., Karlsson, E.K., Kulbokas, E.J., 3rd, Gingeras, T.R., et al. (2005). 
 101 
Genomic maps and comparative analysis of histone modifications in human and mouse. 
Cell 120, 169-181. 
Bird, A.P., and Wolffe, A.P. (1999). Methylation-induced repression--belts, braces, and 
chromatin. Cell 99, 451-454. 
Bouchard, J., and Momparler, R.L. (1983). Incorporation of 5-Aza-2'-deoxycytidine-5'-
triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA 
methylase. Mol Pharmacol 24, 109-114. 
Bracken, A.P., Kleine-Kohlbrecher, D., Dietrich, N., Pasini, D., Gargiulo, G., Beekman, 
C., Theilgaard-Monch, K., Minucci, S., Porse, B.T., Marine, J.C., et al. (2007a). The 
Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in 
senescent cells. Genes Dev 21, 525-530. 
Bracken, A.P., Kleine-Kohlbrecher, D., Dietrich, N., Pasini, D., Gargiulo, G., Beekman, 
C., Theilgaard-Monch, K., Minucci, S., Porse, B.T., Marine, J.C., et al. (2007b). The 
Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in 
senescent cells. Genes & Dev 21, 525-530. 
Brookes, S., Rowe, J., Ruas, M., Llanos, S., Clark, P.A., Lomax, M., James, M.C., 
Vatcheva, R., Bates, S., Vousden, K.H., et al. (2002). INK4a-deficient human diploid 
fibroblasts are resistant to RAS-induced senescence. EMBO J 21, 2936-2945. 
Bruggeman, S.W., Valk-Lingbeek, M.E., van der Stoop, P.P., Jacobs, J.J., Kieboom, K., 
Tanger, E., Hulsman, D., Leung, C., Arsenijevic, Y., Marino, S., et al. (2005). Ink4a and 
Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-
deficient mice. Genes Dev 19, 1438-1443. 
Cameron, E.E., Bachman, K.E., Myohanen, S., Herman, J.G., and Baylin, S.B. (1999). 
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes 
silenced in cancer. Nat Genet 21, 103-107. 
Cao, R., Tsukada, Y., and Zhang, Y. (2005a). Role of Bmi-1 and Ring1A in H2A 
ubiquitylation and Hox gene silencing. Mol Cell 20, 845-854. 
Cao, R., Tsukada, Y., and Zhang, Y. (2005b). Role of Bmi-1 and Ring1A in H2A 
ubiquitylation and Hox gene silencing. Mol Cell 20, 845-854. 
 102 
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R.S., 
and Zhang, Y. (2002). Role of histone H3 lysine 27 methylation in Polycomb-group 
silencing. Science (New York, NY 298, 1039-1043. 
Caretti, G., Di Padova, M., Micales, B., Lyons, G.E., and Sartorelli, V. (2004). The 
Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle 
differentiation. Genes Dev 18, 2627-2638. 
Cheng, J.C., Matsen, C.B., Gonzales, F.A., Ye, W., Greer, S., Marquez, V.E., Jones, 
P.A., and Selker, E.U. (2003). Inhibition of DNA methylation and reactivation of 
silenced genes by zebularine. J Natl Cancer Inst 95, 399-409. 
Czermin, B., Melfi, R., McCabe, D., Seitz, V., Imhof, A., and Pirrotta, V. (2002). 
Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase 
activity that marks chromosomal Polycomb sites. Cell 111, 185-196. 
de Stanchina, E., McCurrach, M.E., Zindy, F., Shieh, S.Y., Ferbeyre, G., Samuelson, 
A.V., Prives, C., Roussel, M.F., Sherr, C.J., and Lowe, S.W. (1998). E1A signaling to 
p53 involves the p19(ARF) tumor suppressor. Genes Dev 12, 2434-2442. 
DeGregori, J., Leone, G., Miron, A., Jakoi, L., and Nevins, J.R. (1997). Distinct roles for 
E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A 94, 7245-
7250. 
Deng, Q., Liao, R., Wu, B.L., and Sun, P. (2004). High intensity ras signaling induces 
premature senescence by activating p38 pathway in primary human fibroblasts. J Biol 
Chem 279, 1050-1059. 
Dietrich, N., Bracken, A.P., Trinh, E., Schjerling, C.K., Koseki, H., Rappsilber, J., Helin, 
K., and Hansen, K.H. (2007). Bypass of senescence by the polycomb group protein 
CBX8 through direct binding to the INK4A-ARF locus. Embo J 26, 1637-1648. 
Drayton, S., Rowe, J., Jones, R., Vatcheva, R., Cuthbert-Heavens, D., Marshall, J., Fried, 
M., and Peters, G. (2003). Tumor suppressor p16INK4a determines sensitivity of human 
cells to transformation by cooperating cellular oncogenes. Cancer Cell 4, 301-310. 
Dyson, N. (1998). The regulation of E2F by pRB-family proteins. Genes Dev 12, 2245-
2262. 
 103 
Eden, S., Hashimshony, T., Keshet, I., Cedar, H., and Thorne, A.W. (1998). DNA 
methylation models histone acetylation. Nature 394, 842. 
Elderkin, S., Maertens, G.N., Endoh, M., Mallery, D.L., Morrice, N., Koseki, H., Peters, 
G., Brockdorff, N., and Hiom, K. (2007). A phosphorylated form of Mel-18 targets the 
Ring1B histone H2A ubiquitin ligase to chromatin. Mol Cell 28, 107-120. 
Esteller, M. (2002). CpG island hypermethylation and tumor suppressor genes: a 
booming present, a brighter future. Oncogene 21, 5427-5440. 
Esteller, M., Cordon-Cardo, C., Corn, P.G., Meltzer, S.J., Pohar, K.S., Watkins, D.N., 
Capella, G., Peinado, M.A., Matias-Guiu, X., Prat, J., et al. (2001a). p14ARF silencing 
by promoter hypermethylation mediates abnormal intracellular localization of MDM2. 
Cancer Res 61, 2816-2821. 
Esteller, M., Corn, P.G., Baylin, S.B., and Herman, J.G. (2001b). A gene 
hypermethylation profile of human cancer. Cancer research 61, 3225-3229. 
Esteller, M., and Herman, J.G. (2002). Cancer as an epigenetic disease: DNA methylation 
and chromatin alterations in human tumours. J Pathol 196, 1-7. 
Evan, G.I., Wyllie, A.H., Gilbert, C.S., Littlewood, T.D., Land, H., Brooks, M., Waters, 
C.M., Penn, L.Z., and Hancock, D.C. (1992). Induction of apoptosis in fibroblasts by c-
myc protein. Cell 69, 119-128. 
Fahrner, J.A., Eguchi, S., Herman, J.G., and Baylin, S.B. (2002). Dependence of histone 
modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 62, 
7213-7218. 
Ferbeyre, G., de Stanchina, E., Querido, E., Baptiste, N., Prives, C., and Lowe, S.W. 
(2000). PML is induced by oncogenic ras and promotes premature senescence. Genes 
Dev 14, 2015-2027. 
Fujita, N., Watanabe, S., Ichimura, T., Tsuruzoe, S., Shinkai, Y., Tachibana, M., Chiba, 
T., and Nakao, M. (2003). Methyl-CpG binding domain 1 (MBD1) interacts with the 
Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional 
repression. J Biol Chem 278, 24132-24138. 
 104 
Fuks, F., Hurd, P.J., Deplus, R., and Kouzarides, T. (2003a). The DNA 
methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. 
Nucleic Acids Res 31, 2305-2312. 
Fuks, F., Hurd, P.J., Wolf, D., Nan, X., Bird, A.P., and Kouzarides, T. (2003b). The 
methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J 
Biol Chem 278, 4035-4040. 
Gallinari, P., Di Marco, S., Jones, P., Pallaoro, M., and Steinkuhler, C. (2007). HDACs, 
histone deacetylation and gene transcription: from molecular biology to cancer 
therapeutics. Cell Res 17, 195-211. 
Gardiner-Garden, M., and Frommer, M. (1987). CpG islands in vertebrate genomes. J 
Mol Biol 196, 261-282. 
Gil, J., Bernard, D., Martinez, D., and Beach, D. (2004). Polycomb CBX7 has a unifying 
role in cellular lifespan. Nat Cell Biol 6, 67-72. 
Gil, J., and Peters, G. (2006). Regulation of the INK4b-ARF-INK4a tumour suppressor 
locus: all for one or one for all. Nat Rev Mol Cell Biol 7, 667-677. 
Goebl, M.G. (1991). The bmi-1 and mel-18 gene products define a new family of DNA-
binding proteins involved in cell proliferation and tumorigenesis. Cell 66, 623. 
Gonzalez-Zulueta, M., Bender, C.M., Yang, A.S., Nguyen, T., Beart, R.W., Van Tornout, 
J.M., and Jones, P.A. (1995). Methylation of the 5' CpG island of the p16/CDKN2 tumor 
suppressor gene in normal and transformed human tissues correlates with gene silencing. 
Cancer Res 55, 4531-4535. 
Gonzalez, S., Klatt, P., Delgado, S., Conde, E., Lopez-Rios, F., Sanchez-Cespedes, M., 
Mendez, J., Antequera, F., and Serrano, M. (2006). Oncogenic activity of Cdc6 through 
repression of the INK4/ARF locus. Nature 440, 702-706. 
Grandori, C., Wu, K.J., Fernandez, P., Ngouenet, C., Grim, J., Clurman, B.E., Moser, 
M.J., Oshima, J., Russell, D.W., Swisshelm, K., et al. (2003). Werner syndrome protein 
limits MYC-induced cellular senescence. Genes Dev 17, 1569-1574. 
 105 
Greger, V., Passarge, E., Hopping, W., Messmer, E., and Horsthemke, B. (1989). 
Epigenetic changes may contribute to the formation and spontaneous regression of 
retinoblastoma. Hum Genet 83, 155-158. 
Groth, A., Weber, J.D., Willumsen, B.M., Sherr, C.J., and Roussel, M.F. (2000). 
Oncogenic Ras induces p19ARF and growth arrest in mouse embryo fibroblasts lacking 
p21Cip1 and p27Kip1 without activating cyclin D-dependent kinases. J Biol Chem 275, 
27473-27480. 
Guney, I., Wu, S., and Sedivy, J.M. (2006). Reduced c-Myc signaling triggers telomere-
independent senescence by regulating Bmi-1 and p16(INK4a). Proc Natl Acad Sci U S A 
103, 3645-3650. 
Haq, R., Brenton, J.D., Takahashi, M., Finan, D., Finkielsztein, A., Damaraju, S., 
Rottapel, R., and Zanke, B. (2002). Constitutive p38HOG mitogen-activated protein 
kinase activation induces permanent cell cycle arrest and senescence. Cancer Res 62, 
5076-5082. 
Harris, S.L., and Levine, A.J. (2005). The p53 pathway: positive and negative feedback 
loops. Oncogene 24, 2899-2908. 
Haupt, Y., Alexander, W.S., Barri, G., Klinken, S.P., and Adams, J.M. (1991). Novel 
zinc finger gene implicated as myc collaborator by retrovirally accelerated 
lymphomagenesis in E mu-myc transgenic mice. Cell 65, 753-763. 
Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes the rapid 
degradation of p53. Nature 387, 296-299. 
He, Y., Armanious, M.K., Thomas, M.J., and Cress, W.D. (2000). Identification of E2F-
3B, an alternative form of E2F-3 lacking a conserved N-terminal region. Oncogene 19, 
3422-3433. 
Heard, E. (2004). Recent advances in X-chromosome inactivation. Curr Opin Cell Biol 
16, 247-255. 
Herman, J.G., Latif, F., Weng, Y., Lerman, M.I., Zbar, B., Liu, S., Samid, D., Duan, D.S., 
Gnarra, J.R., Linehan, W.M., et al. (1994). Silencing of the VHL tumor-suppressor gene 
by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91, 9700-9704. 
 106 
Herman, J.G., Merlo, A., Mao, L., Lapidus, R.G., Issa, J.P., Davidson, N.E., Sidransky, 
D., and Baylin, S.B. (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently 
associated with aberrant DNA methylation in all common human cancers. Cancer Res 55, 
4525-4530. 
Hiebert, S.W., Packham, G., Strom, D.K., Haffner, R., Oren, M., Zambetti, G., and 
Cleveland, J.L. (1995). E2F-1:DP-1 induces p53 and overrides survival factors to trigger 
apoptosis. Mol Cell Biol 15, 6864-6874. 
Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. (1991). p53 mutations in 
human cancers. Science (New York, NY 253, 49-53. 
Honda, R., Tanaka, H., and Yasuda, H. (1997). Oncoprotein MDM2 is a ubiquitin ligase 
E3 for tumor suppressor p53. FEBS Lett 420, 25-27. 
Iaquinta, P.J., Aslanian, A., and Lees, J.A. (2005). Regulation of the Arf/p53 tumor 
surveillance network by E2F. Cold Spring Harb Symp Quant Biol 70, 309-316. 
Inoue, K., Roussel, M.F., and Sherr, C.J. (1999). Induction of ARF tumor suppressor 
gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci U 
S A 96, 3993-3998. 
Ishida, A., Asano, H., Hasegawa, M., Koseki, H., Ono, T., Yoshida, M.C., Taniguchi, M., 
and Kanno, M. (1993). Cloning and chromosome mapping of the human Mel-18 gene 
which encodes a DNA-binding protein with a new 'RING-finger' motif. Gene 129, 249-
255. 
Ito, S., D'Alessio, A.C., Taranova, O.V., Hong, K., Sowers, L.C., and Zhang, Y. (2010). 
Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell 
mass specification. Nature 466, 1129-1133. 
Iwasa, H., Han, J., and Ishikawa, F. (2003). Mitogen-activated protein kinase p38 defines 
the common senescence-signalling pathway. Genes Cells 8, 131-144. 
Iwase, S., Lan, F., Bayliss, P., de la Torre-Ubieta, L., Huarte, M., Qi, H.H., Whetstine, 
J.R., Bonni, A., Roberts, T.M., and Shi, Y. (2007). The X-linked mental retardation gene 
SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell 128, 1077-
1088. 
 107 
Jacobs, J.J., Kieboom, K., Marino, S., DePinho, R.A., and van Lohuizen, M. (1999a). The 
oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence 
through the ink4a locus. Nature 397, 164-168. 
Jacobs, J.J., Scheijen, B., Voncken, J.W., Kieboom, K., Berns, A., and van Lohuizen, M. 
(1999b). Bmi-1 collaborates with c-myc in tumorigenesis by inhibiting c-Myc-induced 
apoptosis via INK4a/ARF. Genes & Dev 13, 2678-2690. 
Johnson, D.G., Cress, W.D., Jakoi, L., and Nevins, J.R. (1994). Oncogenic capacity of 
the E2F1 gene. Proc Natl Acad Sci U S A 91, 12823-12827. 
Jones, P.L., Veenstra, G.J., Wade, P.A., Vermaak, D., Kass, S.U., Landsberger, N., 
Strouboulis, J., and Wolffe, A.P. (1998). Methylated DNA and MeCP2 recruit histone 
deacetylase to repress transcription. Nat Genet 19, 187-191. 
Kamijo, T., Weber, J.D., Zambetti, G., Zindy, F., Roussel, M.F., and Sherr, C.J. (1998). 
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. 
Proc Natl Acad Sci U S A 95, 8292-8297. 
Kel, A.E., Kel-Margoulis, O.V., Farnham, P.J., Bartley, S.M., Wingender, E., and Zhang, 
M.Q. (2001). Computer-assisted identification of cell cycle-related genes: new targets for 
E2F transcription factors. J Mol Biol 309, 99-120. 
Kheradmand Kia, S., Solaimani Kartalaei, P., Farahbakhshian, E., Pourfarzad, F., von 
Lindern, M., and Verrijzer, C.P. (2009). EZH2-dependent chromatin looping controls 
INK4a and INK4b, but not ARF, during human progenitor cell differentiation and 
cellular senescence. Epigenetics Chromatin 2, 16. 
Kim, W.Y., and Sharpless, N.E. (2006). The regulation of INK4/ARF in cancer and 
aging. Cell 127, 265-275. 
Klose, R.J., Yan, Q., Tothova, Z., Yamane, K., Erdjument-Bromage, H., Tempst, P., 
Gilliland, D.G., Zhang, Y., and Kaelin, W.G., Jr. (2007). The retinoblastoma binding 
protein RBP2 is an H3K4 demethylase. Cell 128, 889-900. 
Komori, H., Enomoto, M., Nakamura, M., Iwanaga, R., and Ohtani, K. (2005). Distinct 
E2F-mediated transcriptional program regulates p14ARF gene expression. Embo J 24, 
3724-3736. 
 108 
Kotake, Y., Cao, R., Viatour, P., Sage, J., Zhang, Y., and Xiong, Y. (2007a). pRB family 
proteins are required for H3K27 trimethylation and Polycomb repression complexes 
binding to and silencing p16INK4a tumor suppressor gene. Genes & Dev 21, 49-54. 
Kotake, Y., Cao, R., Viatour, P., Sage, J., Zhang, Y., and Xiong, Y. (2007b). pRB family 
proteins are required for H3K27 trimethylation and Polycomb repression complexes 
binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev 21, 49-54. 
Kotake, Y., Zeng, Y., and Xiong, Y. (2009). DDB1-CUL4 and MLL1 mediate oncogene-
induced p16INK4a activation. Cancer Res 69, 1809-1814. 
Kouzarides, T. (2007). Chromatin modifications and their function. Cell 128, 693-705. 
Kriaucionis, S., and Heintz, N. (2009). The nuclear DNA base 5-hydroxymethylcytosine 
is present in Purkinje neurons and the brain. Science (New York, NY 324, 929-930. 
Krishnamurthy, J., Torrice, C., Ramsey, M.R., Kovalev, G.I., Al-Regaiey, K., Su, L., and 
Sharpless, N.E. (2004). Ink4a/Arf expression is a biomarker of aging. J Clin Invest 114, 
1299-1307. 
Kubbutat, M.H., Jones, S.N., and Vousden, K.H. (1997). Regulation of p53 stability by 
Mdm2. Nature 387, 299-303. 
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., and Reinberg, D. 
(2002). Histone methyltransferase activity associated with a human multiprotein complex 
containing the Enhancer of Zeste protein. Genes Dev 16, 2893-2905. 
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., and Jenuwein, T. (2001). Methylation 
of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410, 116-120. 
Laptenko, O., and Prives, C. (2006). Transcriptional regulation by p53: one protein, many 
possibilities. Cell Death Differ 13, 951-961. 
Lehnertz, B., Ueda, Y., Derijck, A.A., Braunschweig, U., Perez-Burgos, L., Kubicek, S., 
Chen, T., Li, E., Jenuwein, T., and Peters, A.H. (2003). Suv39h-mediated histone H3 
lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric 
heterochromatin. Curr Biol 13, 1192-1200. 
 109 
Leone, G., Nuckolls, F., Ishida, S., Adams, M., Sears, R., Jakoi, L., Miron, A., and 
Nevins, J.R. (2000). Identification of a novel E2F3 product suggests a mechanism for 
determining specificity of repression by Rb proteins. Mol Cell Biol 20, 3626-3632. 
Leonhardt, H., Page, A.W., Weier, H.U., and Bestor, T.H. (1992). A targeting sequence 
directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell 71, 
865-873. 
Lessard, J., Schumacher, A., Thorsteinsdottir, U., van Lohuizen, M., Magnuson, T., and 
Sauvageau, G. (1999). Functional antagonism of the Polycomb-Group genes eed and 
Bmi1 in hemopoietic cell proliferation. Genes Dev 13, 2691-2703. 
Leung, C., Lingbeek, M., Shakhova, O., Liu, J., Tanger, E., Saremaslani, P., Van 
Lohuizen, M., and Marino, S. (2004). Bmi1 is essential for cerebellar development and is 
overexpressed in human medulloblastomas. Nature 428, 337-341. 
Levine, A.J., Momand, J., and Finlay, C.A. (1991). The p53 tumour suppressor gene. 
Nature 351, 453-456. 
Levine, S.S., Weiss, A., Erdjument-Bromage, H., Shao, Z., Tempst, P., and Kingston, 
R.E. (2002). The core of the polycomb repressive complex is compositionally and 
functionally conserved in flies and humans. Mol Cell Biol 22, 6070-6078. 
Li, E., Beard, C., and Jaenisch, R. (1993). Role for DNA methylation in genomic 
imprinting. Nature 366, 362-365. 
Li, E., Bestor, T.H., and Jaenisch, R. (1992). Targeted mutation of the DNA 
methyltransferase gene results in embryonic lethality. Cell 69, 915-926. 
Lin, A.W., Barradas, M., Stone, J.C., van Aelst, L., Serrano, M., and Lowe, S.W. (1998). 
Premature senescence involving p53 and p16 is activated in response to constitutive 
MEK/MAPK mitogenic signaling. Genes Dev 12, 3008-3019. 
Lin, A.W., and Lowe, S.W. (2001). Oncogenic ras activates the ARF-p53 pathway to 
suppress epithelial cell transformation. Proc Natl Acad Sci U S A 98, 5025-5030. 
Lin, J., Chen, J., and Levine, A.J. (1994). Several hydrophobic amino acids in the p53 
amino-terminal domain are required for transcriptional activation, binding to MDM-2 and 
the adenovirus 5 E1B 55-kD protein. Genes & Dev 8, 1235-1246. 
 110 
Lin, T., Chao, C., Saito, S., Mazur, S.J., Murphy, M.E., Appella, E., and Xu, Y. (2005). 
p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog 
expression. Nat Cell Biol 7, 165-171. 
Lloyd, A.C. (2000). p53: only ARF the story. Nat Cell Biol 2, E48-50. 
Lomazzi, M., Moroni, M.C., Jensen, M.R., Frittoli, E., and Helin, K. (2002). Suppression 
of the p53- or pRB-mediated G1 checkpoint is required for E2F-induced S-phase entry. 
Nat Genet 31, 190-194. 
Lozano, G. (2007). The oncogenic roles of p53 mutants in mouse models. Curr Opin 
Genet Dev 17, 66-70. 
Lukas, J., Petersen, B.O., Holm, K., Bartek, J., and Helin, K. (1996). Deregulated 
expression of E2F family members induces S-phase entry and overcomes p16INK4A-
mediated growth suppression. Mol Cell Biol 16, 1047-1057. 
Lund, A.H., and van Lohuizen, M. (2004). Polycomb complexes and silencing 
mechanisms. Curr Opin Cell Biol 16, 239-246. 
Luo, R.X., Postigo, A.A., and Dean, D.C. (1998). Rb interacts with histone deacetylase to 
repress transcription. Cell 92, 463-473. 
Maertens, G.N., El Messaoudi-Aubert, S., Racek, T., Stock, J.K., Nicholls, J., Rodriguez-
Niedenfuhr, M., Gil, J., and Peters, G. (2009). Several distinct polycomb complexes 
regulate and co-localize on the INK4a tumor suppressor locus. PLoS One 4, e6380. 
Matheu, A., Klatt, P., and Serrano, M. (2005). Regulation of the INK4a/ARF locus by 
histone deacetylase inhibitors. J Biol Chem 280, 42433-42441. 
Melendez, B., Malumbres, M., de Castro, I.P., Santos, J., Pellicer, A., and Fernandez-
Piqueras, J. (2000). Characterization of the murine p19(ARF) promoter CpG island and 
its methylation pattern in primary lymphomas. Carcinogenesis 21, 817-821. 
Menendez, D., Inga, A., and Resnick, M.A. (2009). The expanding universe of p53 
targets. Nat Rev Cancer 9, 724-737. 
 111 
Merlo, A., Herman, J.G., Mao, L., Lee, D.J., Gabrielson, E., Burger, P.C., Baylin, S.B., 
and Sidransky, D. (1995). 5' CpG island methylation is associated with transcriptional 
silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1, 
686-692. 
Michaloglou, C., Vredeveld, L.C., Soengas, M.S., Denoyelle, C., Kuilman, T., van der 
Horst, C.M., Majoor, D.M., Shay, J.W., Mooi, W.J., and Peeper, D.S. (2005). 
BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-
724. 
Molofsky, A.V., He, S., Bydon, M., Morrison, S.J., and Pardal, R. (2005). Bmi-1 
promotes neural stem cell self-renewal and neural development but not mouse growth 
and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 19, 
1432-1437. 
Momand, J., Zambetti, G.P., Olson, D.C., George, D., and Levine, A.J. (1992). The 
mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-
mediated transactivation. Cell 69, 1237-1245. 
Muller, J., Hart, C.M., Francis, N.J., Vargas, M.L., Sengupta, A., Wild, B., Miller, E.L., 
O'Connor, M.B., Kingston, R.E., and Simon, J.A. (2002). Histone methyltransferase 
activity of a Drosophila Polycomb group repressor complex. Cell 111, 197-208. 
Munzel, M., Globisch, D., Bruckl, T., Wagner, M., Welzmiller, V., Michalakis, S., 
Muller, M., Biel, M., and Carell, T. (2010). Quantification of the sixth DNA base 
hydroxymethylcytosine in the brain. Angew Chem Int Ed Engl 49, 5375-5377. 
Murphy, M., Ahn, J., Walker, K.K., Hoffman, W.H., Evans, R.M., Levine, A.J., and 
George, D.L. (1999). Transcriptional repression by wild-type p53 utilizes histone 
deacetylases, mediated by interaction with mSin3a. Genes Dev 13, 2490-2501. 
Nan, X., Ng, H.H., Johnson, C.A., Laherty, C.D., Turner, B.M., Eisenman, R.N., and 
Bird, A. (1998). Transcriptional repression by the methyl-CpG-binding protein MeCP2 
involves a histone deacetylase complex. Nature 393, 386-389. 
Nevins, J.R. (1998). Toward an understanding of the functional complexity of the E2F 
and retinoblastoma families. Cell Growth Differ 9, 585-593. 
 112 
Ng, H.H., Zhang, Y., Hendrich, B., Johnson, C.A., Turner, B.M., Erdjument-Bromage, 
H., Tempst, P., Reinberg, D., and Bird, A. (1999). MBD2 is a transcriptional repressor 
belonging to the MeCP1 histone deacetylase complex. Nat Genet 23, 58-61. 
Nguyen, C.T., Weisenberger, D.J., Velicescu, M., Gonzales, F.A., Lin, J.C., Liang, G., 
and Jones, P.A. (2002). Histone H3-lysine 9 methylation is associated with aberrant gene 
silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res 
62, 6456-6461. 
Ohtani, N., Zebedee, Z., Huot, T.J., Stinson, J.A., Sugimoto, M., Ohashi, Y., Sharrocks, 
A.D., Peters, G., and Hara, E. (2001). Opposing effects of Ets and Id proteins on 
p16INK4a expression during cellular senescence. Nature 409, 1067-1070. 
Okano, M., Bell, D.W., Haber, D.A., and Li, E. (1999). DNA methyltransferases Dnmt3a 
and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99, 
247-257. 
Otsuka, K., Kato, S., Kakudo, Y., Mashiko, S., Shibata, H., and Ishioka, C. (2007). The 
screening of the second-site suppressor mutations of the common p53 mutants. Int J 
Cancer 121, 559-566. 
Otte, A.P., and Kwaks, T.H. (2003). Gene repression by Polycomb group protein 
complexes: a distinct complex for every occasion? Curr Opin Genet Dev 13, 448-454. 
Otto, A., and Deppert, W. (1993). Upregulation of mdm-2 expression in Meth A tumor 
cells tolerating wild-type p53. Oncogene 8, 2591-2603. 
Palmero, I., Pantoja, C., and Serrano, M. (1998). p19ARF links the tumour suppressor 
p53 to Ras. Nature 395, 125-126. 
Parisi, T., Pollice, A., Di Cristofano, A., Calabro, V., and La Mantia, G. (2002). 
Transcriptional regulation of the human tumor suppressor p14(ARF) by E2F1, E2F2, 
E2F3, and Sp1-like factors. Biochem Biophys Res Commun 291, 1138-1145. 
Park, I.K., Qian, D., Kiel, M., Becker, M.W., Pihalja, M., Weissman, I.L., Morrison, S.J., 
and Clarke, M.F. (2003). Bmi-1 is required for maintenance of adult self-renewing 
haematopoietic stem cells. Nature 423, 302-305. 
 113 
Pasini, D., Hansen, K.H., Christensen, J., Agger, K., Cloos, P.A., and Helin, K. (2008). 
Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and 
Polycomb-Repressive Complex 2. Genes Dev 22, 1345-1355. 
Phillips, A.C., Ernst, M.K., Bates, S., Rice, N.R., and Vousden, K.H. (1999). E2F-1 
potentiates cell death by blocking antiapoptotic signaling pathways. Mol Cell 4, 771-781. 
Phillips, A.C., and Vousden, K.H. (2001). E2F-1 induced apoptosis. Apoptosis 6, 173-
182. 
Pomerantz, J., Schreiber-Agus, N., Liegeois, N.J., Silverman, A., Alland, L., Chin, L., 
Potes, J., Chen, K., Orlow, I., Lee, H.W., et al. (1998). The Ink4a tumor suppressor gene 
product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 
92, 713-723. 
Qin, X.Q., Livingston, D.M., Kaelin, W.G., Jr., and Adams, P.D. (1994). Deregulated 
transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. 
Proc Natl Acad Sci U S A 91, 10918-10922. 
Quelle, D.E., Zindy, F., Ashmun, R.A., and Sherr, C.J. (1995). Alternative reading 
frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of 
inducing cell cycle arrest. Cell 83, 993-1000. 
Rhee, I., Bachman, K.E., Park, B.H., Jair, K.W., Yen, R.W., Schuebel, K.E., Cui, H., 
Feinberg, A.P., Lengauer, C., Kinzler, K.W., et al. (2002). DNMT1 and DNMT3b 
cooperate to silence genes in human cancer cells. Nature 416, 552-556. 
Riley, T., Sontag, E., Chen, P., and Levine, A. (2008). Transcriptional control of human 
p53-regulated genes. Nat Rev Mol Cell Biol 9, 402-412. 
Robertson, K.D., and Jones, P.A. (1998). The human ARF cell cycle regulatory gene 
promoter is a CpG island which can be silenced by DNA methylation and down-
regulated by wild-type p53. Mol Cell Biol 18, 6457-6473. 
Santi, D.V., Garrett, C.E., and Barr, P.J. (1983). On the mechanism of inhibition of DNA-
cytosine methyltransferases by cytosine analogs. Cell 33, 9-10. 
 114 
Santi, D.V., Norment, A., and Garrett, C.E. (1984). Covalent bond formation between a 
DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci 
U S A 81, 6993-6997. 
Sarma, K., and Reinberg, D. (2005). Histone variants meet their match. Nat Rev Mol Cell 
Biol 6, 139-149. 
Sarraf, S.A., and Stancheva, I. (2004). Methyl-CpG binding protein MBD1 couples 
histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin 
assembly. Mol Cell 15, 595-605. 
Scott, C.L., Gil, J., Hernando, E., Teruya-Feldstein, J., Narita, M., Martinez, D., 
Visakorpi, T., Mu, D., Cordon-Cardo, C., Peters, G., et al. (2007). Role of the chromobox 
protein CBX7 in lymphomagenesis. Proc Natl Acad Sci U S A 104, 5389-5394. 
Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997). 
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 
and p16INK4a. Cell 88, 593-602. 
Sharpless, N.E. (2005). INK4a/ARF: a multifunctional tumor suppressor locus. Mutat 
Res 576, 22-38. 
Sherr, C.J. (1998). Tumor surveillance via the ARF-p53 pathway. Genes Dev 12, 2984-
2991. 
Sherr, C.J. (2001). The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell 
Biol 2, 731-737. 
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J.R., Cole, P.A., Casero, R.A., and 
Shi, Y. (2004). Histone demethylation mediated by the nuclear amine oxidase homolog 
LSD1. Cell 119, 941-953. 
Sreeramaneni, R., Chaudhry, A., McMahon, M., Sherr, C.J., and Inoue, K. (2005). Ras-
Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol 25, 
220-232. 
Stancheva, I. (2005). Caught in conspiracy: cooperation between DNA methylation and 
histone H3K9 methylation in the establishment and maintenance of heterochromatin. 
Biochem Cell Biol 83, 385-395. 
 115 
Stott, F.J., Bates, S., James, M.C., McConnell, B.B., Starborg, M., Brookes, S., Palmero, 
I., Ryan, K., Hara, E., Vousden, K.H., et al. (1998). The alternative product from the 
human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 
and MDM2. EMBO J 17, 5001-5014. 
Tachibana, M., Sugimoto, K., Nozaki, M., Ueda, J., Ohta, T., Ohki, M., Fukuda, M., 
Takeda, N., Niida, H., Kato, H., et al. (2002). G9a histone methyltransferase plays a 
dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early 
embryogenesis. Genes Dev 16, 1779-1791. 
Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., Agarwal, 
S., Iyer, L.M., Liu, D.R., Aravind, L., et al. (2009). Conversion of 5-methylcytosine to 5-
hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science (New York, 
NY 324, 930-935. 
Tahiliani, M., Mei, P., Fang, R., Leonor, T., Rutenberg, M., Shimizu, F., Li, J., Rao, A., 
and Shi, Y. (2007). The histone H3K4 demethylase SMCX links REST target genes to X-
linked mental retardation. Nature 447, 601-605. 
Tariq, M., Saze, H., Probst, A.V., Lichota, J., Habu, Y., and Paszkowski, J. (2003). 
Erasure of CpG methylation in Arabidopsis alters patterns of histone H3 methylation in 
heterochromatin. Proc Natl Acad Sci U S A 100, 8823-8827. 
Thut, C.J., Goodrich, J.A., and Tjian, R. (1997). Repression of p53-mediated 
transcription by MDM2: a dual mechanism. Genes Dev 11, 1974-1986. 
Tie, F., Furuyama, T., Prasad-Sinha, J., Jane, E., and Harte, P.J. (2001). The Drosophila 
Polycomb Group proteins ESC and E(Z) are present in a complex containing the histone-
binding protein p55 and the histone deacetylase RPD3. Development 128, 275-286. 
Trimarchi, J.M., and Lees, J.A. (2002). Sibling rivalry in the E2F family. Nat Rev Mol 
Cell Biol 3, 11-20. 
Turner, B.M. (2000). Histone acetylation and an epigenetic code. Bioessays 22, 836-845. 
Umbarger, H.E. (1956). Evidence for a negative-feedback mechanism in the biosynthesis 
of isoleucine. Science 123, 848. 
 116 
Valk-Lingbeek, M.E., Bruggeman, S.W., and van Lohuizen, M. (2004). Stem cells and 
cancer; the polycomb connection. Cell 118, 409-418. 
van der Lugt, N.M., Domen, J., Linders, K., van Roon, M., Robanus-Maandag, E., te 
Riele, H., van der Valk, M., Deschamps, J., Sofroniew, M., van Lohuizen, M., et al. 
(1994). Posterior transformation, neurological abnormalities, and severe hematopoietic 
defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev 8, 757-
769. 
van der Vlag, J., and Otte, A.P. (1999). Transcriptional repression mediated by the human 
polycomb-group protein EED involves histone deacetylation. Nat Genet 23, 474-478. 
van Lohuizen, M., Verbeek, S., Scheijen, B., Wientjens, E., van der Gulden, H., and 
Berns, A. (1991). Identification of cooperating oncogenes in E mu-myc transgenic mice 
by provirus tagging. Cell 65, 737-752. 
Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., 
Kammlott, U., Lukacs, C., Klein, C., et al. (2004). In vivo activation of the p53 pathway 
by small-molecule antagonists of MDM2. Science 303, 844-848. 
Vousden, K.H., and Prives, C. (2009). Blinded by the Light: The Growing Complexity of 
p53. Cell 137, 413-431. 
Wang, H., Wang, L., Erdjument-Bromage, H., Vidal, M., Tempst, P., Jones, R.S., and 
Zhang, Y. (2004a). Role of histone H2A ubiquitination in Polycomb silencing. Nature 
431, 873-878. 
Wang, L., Brown, J.L., Cao, R., Zhang, Y., Kassis, J.A., and Jones, R.S. (2004b). 
Hierarchical recruitment of polycomb group silencing complexes. Mol Cell 14, 637-646. 
Wang, L., Brown, J.L., Cao, R., Zhang, Y., Kassis, J.A., and Jones, R.S. (2004c). 
Hierarchical recruitment of polycomb group silencing complexes. Mol Cell 14, 637-646. 
Wang, W., Chen, J.X., Liao, R., Deng, Q., Zhou, J.J., Huang, S., and Sun, P. (2002). 
Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 
mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature 
senescence. Mol Cell Biol 22, 3389-3403. 
 117 
Wei, W., Hemmer, R.M., and Sedivy, J.M. (2001). Role of p14(ARF) in replicative and 
induced senescence of human fibroblasts. Mol Cell Biol 21, 6748-6757. 
Wu, X., Bayle, J.H., Olson, D., and Levine, A.J. (1993a). The p53-mdm-2 autoregulatory 
feedback loop. Genes Dev 7, 1126-1132. 
Wu, X., Bayle, J.H., Olson, D., and Levine, A.J. (1993b). The p53-mdm-2 autoregulatory 
feedback loop. Genes & Dev 7, 1126-1132. 
Wu, X., and Levine, A.J. (1994). p53 and E2F-1 cooperate to mediate apoptosis. Proc 
Natl Acad Sci U S A 91, 3602-3606. 
Yamakoshi, K., Takahashi, A., Hirota, F., Nakayama, R., Ishimaru, N., Kubo, Y., Mann, 
D.J., Ohmura, M., Hirao, A., Saya, H., et al. (2009). Real-time in vivo imaging of 
p16Ink4a reveals cross talk with p53. J Cell Biol 186, 393-407. 
Yamane, K., Tateishi, K., Klose, R.J., Fang, J., Fabrizio, L.A., Erdjument-Bromage, H., 
Taylor-Papadimitriou, J., Tempst, P., and Zhang, Y. (2007). PLU-1 is an H3K4 
demethylase involved in transcriptional repression and breast cancer cell proliferation. 
Mol Cell 25, 801-812. 
Yarosh, W., Barrientos, T., Esmailpour, T., Lin, L., Carpenter, P.M., Osann, K., Anton-
Culver, H., and Huang, T. (2008). TBX3 is overexpressed in breast cancer and represses 
p14 ARF by interacting with histone deacetylases. Cancer Res 68, 693-699. 
Yoon, H.G., Chan, D.W., Reynolds, A.B., Qin, J., and Wong, J. (2003). N-CoR mediates 
DNA methylation-dependent repression through a methyl CpG binding protein Kaiso. 
Mol Cell 12, 723-734. 
Zhang, Y., and Xiong, Y. (2001). Control of p53 ubiquitination and nuclear export by 
MDM2 and ARF. Cell Growth Differ 12, 175-186. 
Zhang, Y., Xiong, Y., and Yarbrough, W.G. (1998). ARF promotes MDM2 degradation 
and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor 
suppression pathways. Cell 92, 725-734. 
Zhu, J., Woods, D., McMahon, M., and Bishop, J.M. (1998). Senescence of human 
fibroblasts induced by oncogenic Raf. Genes Dev 12, 2997-3007. 
 118 
Zindy, F., Eischen, C.M., Randle, D.H., Kamijo, T., Cleveland, J.L., Sherr, C.J., and 
Roussel, M.F. (1998). Myc signaling via the ARF tumor suppressor regulates p53-
dependent apoptosis and immortalization. Genes Dev 12, 2424-2433. 
 
 
